

## 9.0 Appendices

### Robust Summaries

With reference to the SIDS Data Matrix, the reports have been evaluated and assessed according to the Klimisch criteria as described in previous sections.

- 1 =Reliable without restrictions
- 2 =Reliable with restrictions
- 3 =Not reliable
- 4 =Not assignable

This chapter will focus on each study specifically. The order of presentation will be physico-chemical data, environmental fate data, ecotoxicity and mammalian toxicity.

### List of Abbreviations

|                   |                                       |
|-------------------|---------------------------------------|
| <sup>a</sup>      | Absolute to body weight               |
| -                 | Absent                                |
| +                 | Present                               |
| a.i.              | Active ingredient                     |
| BP                | Boiling point                         |
| d                 | Decrease                              |
| dc                | Decrease (significant)                |
| DR                | Dose related                          |
| F                 | Female                                |
| Hb                | Haemoglobin                           |
| i                 | Increase                              |
| ic                | Increase (significant)                |
| M                 | Male                                  |
| N/A               | Not applicable                        |
| <sup>r</sup>      | Relative to body weight               |
| THCO <sub>2</sub> | Theoretical amount of CO <sub>2</sub> |
| TCO <sub>2</sub>  | Theoretical amount of CO <sub>2</sub> |
| TS                | Test substance                        |
| VP                | Vapour pressure                       |
| WS                | Water solubility                      |

## Appendix 9-1 - Physico-Chemical Data for LAS/ABS

### 9.1.01

**Title** MSDS Rhodacal® 330  
**Date of report** May 14, 1999.  
**GLP** No data  
**Reference** 22  
**Test substance** A (Benzenesulfonic acid, dodecyl-, compd. with isopropylamine (1:1)), purity 90%.  
**Guideline** Not specified.  
**Water solubility** Dispersible.  
**Boiling point** >149°C (at 1.0E5 Pa)  
**Vapor pressure** <3.1E3 Pa (25°C)  
**Klimisch criterium** 4 - Secondary literature

### 9.1.02

**Title** MSDS Rhodacal® CA/70  
**Date of report** August 17, 1999.  
**GLP** No data  
**Reference** 21  
**Test substance** C (Benzenesulfonic acid, dodecyl-,calcium salt), purity 69-71%.  
**Guideline** Not specified.  
**Water solubility** Dispersible.  
**Rev. note** Secondary literature.  
**Klimisch criterium** 4 – Secondary literature

### 9.1.03

**Title** MSDS Casul 70 HF  
**Date of report** 29 February 2000.  
**GLP** No data  
**Reference** 3 and 4  
**Test substance** F (Benzenesulfonic acid, mono-C11-13-branched alkyl derivs., calcium salts), purity 69.5-71.5%.  
**Guideline** Not specified.  
**Boiling point** 117°C (tested as a formulations containing 77% HPV substance plus organic solvent)  
**Vapor pressure** 733 Pa (20°C)  
**Water solubility** Dispersible.  
**Rev. note** The second reference (#3) is an incomplete MSDS for a formulation containing 55% HPV substance plus organic solvent  
**Klimisch criterium** 4 – Secondary literature

## Appendix 9-2 - Environmental Fate Data and Pathways for LAS/ABS

### 9.2.02

|                       |   |
|-----------------------|---|
| <b>Title</b>          | The evaluation of the biodegradation of 910-92 using the OECD screening test method   |
| <b>Date of report</b> | July 2, 1986.   |
| <b>GLP</b>            | Yes.  |
| <b>Reference</b>      | 20  |
| <b>Test substance</b> | B (Benzenesulfonic acid, dodecyl-, compd. with 2,2',2''-nitrilotris(ethanol) (1:1)); Bio-Soft LD-190; Blend consists of 10% triethanolamine dodecyl benzene sulfonate (compound B), 59% nonylphenol ethoxylate, 17% ether sulfate, 10% TEA, <5% cocamide DEA and <5% ethanol.   |
| <b>Test method</b>    | EPA TSCA test guidelines 40 CFR 796.3240, Modified OECD screening test (1985).  |
| <b>Test system</b>    | <p><b>Treatments</b></p> <ul style="list-style-type: none"> <li>- Inoculum: prepared from soil (supernatant of aqueous suspension), secondary effluent from a sewage treatment plant and surface water (1:1:1). Each flask was inoculated with 0.5 mL of the mixed composite inoculum.</li> <li>- 2 flasks treated (medium + inoculum + Bio-Soft LD-190 (20 mg C/L));</li> <li>- 2 flasks positive control (medium + inoculum + sodium benzoate (20 mg C/L));</li> <li>- 2 flasks blank control (medium + inoculum).</li> </ul> <p><b>Procedure</b></p> <p>Aliquots of a stock solution of the test substance (tested conc. 20 mg C/L), mixed composite inoculum (0.5 mL) and nutrient solution (1 L) were mixed. The test mixtures were incubated at 21-23°C for 35 days. Aliquots were removed from each flask on day 0, 7, 14, 21, 27, 28 and 35 for DOC analyses.</p> |

### Results

| day | % degradation [% of day 0 values] |                                       |
|-----|-----------------------------------|---------------------------------------|
|     | Bio-Soft LD-190                   | sodium benzoate (reference substance) |
| 0   | 0                                 | 0                                     |
| 7   | 58                                | 99                                    |
| 14  | 63                                | 100                                   |
| 21  | 68                                | 100                                   |
| 27  | 73                                | 98                                    |
| 28  | 71                                | 100                                   |
| 35  | 72                                | 100                                   |

**Conclusion** Test substance is biodegradable. 71% degraded after 28 days, but did not reach 60% in 10-day window.

**Rev. note** 1. Test substance is a blend containing 10% of substance B. Because (1) the resulting biodegradation (72%) is of the entire blend, (2) substance B is only 10% of the blend, and (3) the other components of the blend are known to be biodegradable, the biodegradation of substance B cannot be accurately estimated from this study.

**Klimisch criterium** 4 Test substance was a blend.

### 9.2.03

|                       |   |
|-----------------------|---|
| <b>Title</b>          | Biotic degradation (modified Sturm test) Evaluation, in an aqueous medium, of the "ultimate" biodegradability of substances: 1736-1A, 1736-1B, 1736-1C, 1736-1D, 1736-1E  |
| <b>Date of report</b> | Not indicated.  |
| <b>GLP</b>            | No data   |
| <b>Reference</b>      | 25  |
| <b>Test substance</b> | D, 1736-1E, purity 96%.   |
| <b>Test method</b>    | OECD 301B.  |
| <b>Test system</b>    | <p><b>Design</b></p> <p>Two control flasks (medium + inoculum 30 mL), 2 treated flasks (medium + inoculum 30 mL + test substance 10 and 20 mg C/L), 1 flask for positive control (medium + inoculum 30 mL + aniline 20 mg C/L).</p> <p><b>Procedure</b></p> <p>Incubation was performed in 5 L flasks containing 3000 mL of mineral solution with test substance and/or inoculum from activated sludge from</p> |

a plant treating predominantly domestic sewage. The inoculum was treated and aerated for 28 days at 22±2°C with CO<sub>2</sub>-free air in the dark. The outgoing air was passed through CO<sub>2</sub>-traps containing Ba(OH)<sub>2</sub>. CO<sub>2</sub> was determined in the traps by back titration of residual Ba(OH)<sub>2</sub> after 1, 4, 5, 7, 8, 11, 12, 13, 15, 18, 20, 22, 26, 27 and 28 days. Samples of the incubate were removed on day 0 and 28 for DOC analysis.

DOC analysis: 94-107% of nominal (day 0); after 28 days: 14.4-17.2% of nominal was left for 1736-1E (82-87% degraded) and 0.3% of nominal for aniline (100% degraded).

For further results see table below.

## Results

## Analysis

| Treatment           | % biodegradation [% of ThCO <sub>2</sub> ] on day: |     |    |    |    |    |    |    |    |    |    |    |    |    |    |
|---------------------|--|-----|----|----|----|----|----|----|----|----|----|----|----|----|----|
|                     | 1  | 4   | 5  | 7  | 8  | 11 | 12 | 13 | 15 | 18 | 20 | 22 | 26 | 27 | 28 |
| 1736-1E (10 mg C/L) | 1.6  | 15  | 28 | 41 | 48 | 56 | 61 | 62 | 64 | 66 | 68 | 70 | 71 | 72 | 73 |
| 1736-1E (20 mg C/L) | 0.3  | 3.9 | 16 | 32 | 40 | 49 | 51 | 53 | 56 | 59 | 61 | 62 | 64 | 65 | 64 |
| Positive control    | 0.0  | 19  | 41 | 58 | 64 | 72 | 76 | 78 | 80 | 83 | 86 | 87 | 89 | 89 | 89 |

**Conclusion** Biodegradable. 64-73% after 28-days at 10 mg/L and 20 mg/L, respectively. Meets the 10-day window for readily biodegradable at 10 mg/L but not at 20 mg/L.

**Klimisch  
Criterium**

1

## 9.2.04

**Title** Bioconcentration of linear alkylbenzene sulfonate (LAS) in bluegill (*Lepomis macrochirus*)

**Date of report** 1981.

**GLP** No.

**Reference** 8

**Test substance** 2 (Benzenesulphonic acid, linear alkyl), 14C-ring-labeled LAS.

**Test method** Not specified.

**Procedure** Bluegill (*Lepomis macrochirus*), 4.0 g and 68 mm, were exposed to isotopically diluted <sup>14</sup>C-ring-labeled-LAS at mean measured concentration of 0.50 mg/L (SD 12%) for 21 days, followed by 14 days of depuration. The test included an untreated control and was conducted under flow-through (~20 changes/24 h) at 17±1°C, pH 7.1 in 60 L aquaria containing water of hardness 35 mg/L (CaCO<sub>3</sub>). After equilibration of the test system (6 days), the control and the treatment were assigned to one tank each with initially 100 and 375 bluegills respectively (loading 12 and 3.2 L/fish/24 h). Fish were fed once daily and the O<sub>2</sub> was measured twice a week: O<sub>2</sub> >60%.

Four fish were removed for radiometric analysis on day 1, 3, 7, 11, 15 and 21 of uptake and on day 1, 2, 3, 5, 7, 9, 11 and 14 of depuration. On day 3, 16 and 21 of uptake and on day 1 and 3 of depuration 16 fish were removed for blood analysis. Water samples for radiometric analyses were taken at day 0, 1, 3, 7, 11, 15 and 21. The water samples were analysed by LSC. The fish for radiometric analysis were blotted dry, weighed and divided into gall bladder, liver, muscle with skin attached, visceral remains containing gills and esophagus and the remaining carcass with head, backbone, fins and tail and analysed by combustion/LSC.

**Results** The radioactivity (r.a.) concentration in the water was 100±12% (mean±SD). LOQ: 0.03 mg LAS/L.

Values for BCF, k<sub>uptake</sub> and k<sub>depuration</sub>, number of days to clear 50 and 90% of the steady state concentration (reached on day 7) were determined using the BIOFAC program.

| Sample               | $K_{uptake}$<br>(L/mg·d) | $K_{depuration}$ (d <sup>-1</sup> ) | BCF (L/mg) | Days to reach 90%<br>of steady state | Days to reach<br>50% of steady<br>state |
|----------------------|--------------------------|-------------------------------------|------------|--------------------------------------|---|
| Whole body           | 25 (8.0) <sup>1</sup>    | 0.24 (8.3)                          | 104 (13)   | 9.7 (10)                             | 2.9 (10)                                |
| Muscle (edible part) | 9 (11)                   | 0.24 (8.3)                          | 36 (14)    | 9.4 (7.9)                            | 2.8 (7.9)                               |
| Gall bladder         | 1461 (17)                | 0.28 (14)                           | 5224 (22)  | 8.2 (13)                             | 2.5 (14)                                |
| Liver                | 82 (26)                  | 0.48 (8.3)                          | 171 (29)   | 4.8 (85)                             | 1.5 (8.3)                               |
| Gill and viscera     | 68 (12)                  | 0.24 (13)                           | 282 (17)   | 9.5 (12)                             | 2.9 (12)                                |
| Blood                | 62 (1.6)                 | 0.26 (3.8)                          | 237 (2.5)  | 8.7 (1.4)                            | 2.6 (0.4)                               |
| Remaining carcass    | 15 (13)                  | 0.24 (8.3)                          | 64 (14)    | 9.7 (9.4)                            | 2.9 (9.3)                               |

<sup>1</sup> ( ) Standard deviation (%)

|                           |  |
|---------------------------|--|
| <b>Conclusion</b>         | Whole fish: steady state uptake reached after 7 days; BCF (based on r.a.) 104; DT <sub>50</sub> depuration r.a. 2.9 day, DT <sub>90</sub> depuration r.a. 9.7 day.   |
| <b>Rev. note</b>          | <ol style="list-style-type: none"> <li>1. Since no results of spiked water or spiked fish were included, the validity of the analytical methods cannot be checked.</li> <li>2. The calculated BCF values are based on total radioactivity. The rapid elimination of LAS, suggests metabolic deactivation. The BCF based on radioactivity is presumably an overestimation of that based on parent.</li> </ol> |
| <b>Klimisch criterium</b> | <ol style="list-style-type: none"> <li>2 No QC analytic samples were included (note 1).</li> </ol>   |

## Appendix 9-3 - Ecotoxicity Data for LAS/ABS

### Acute Toxicity to Fish:

#### 9.3.01

|                       |  |   |
|-----------------------|--|---|
| <b>Title</b>          | Static acute toxicity of CASRN 26264-05-1 to the fathead minnow ( <i>Pimephales promelas</i> ) |   |
| <b>Date of report</b> | April 27, 2000.  |   |
| <b>GLP</b>            | No.  |   |
| <b>Reference</b>      | 10   |   |
| <b>Test substance</b> | A (Benzenesulfonic acid, dodecyl-, compd. with isopropylamine (1:1)), purity 89.4%             |   |
| <b>Guideline</b>      | OECD 203.  |   |
| <b>Stat. method</b>   | None   |   |
| <b>Test system</b>    | <b>Species</b>   | Fathead minnow ( <i>Pimephales promelas</i> ), mean length 17 mm.   |
|                       | <b>No. of fish</b>   | 10/replicate, 2 replicates/treatment.   |
|                       | <b>Concentrations</b>  | Nominal: 3.2, 5.6, 10, 18, 32 and 56 mg/L, water treated controls.  |
|                       | <b>Test conditions</b>   | Static; at 20±2°C in 21 L glass-silicone vessels containing 10 L reconstituted water (pH 8.3, hardness 168 mg/L CaCO <sub>3</sub> ); 16 h light; unfed, loading 0.04 g/l. |
|                       | <b>Phys. meas.</b>   | Daily in all treatments: overall ranges for pH 8.2-8.4; O <sub>2</sub> 87-100%; temperature 20-22°C.  |
|                       | <b>Observations</b>  | Mortality/symptoms at 24, 48, 72 and 96 h.  |

#### Results

| Parameter     | Time [h] | Nominal concentration [mg/L] |     |     |    |    |     |     |
|---------------|----------|------------------------------|-----|-----|----|----|-----|-----|
|               |          | 0                            | 3.2 | 5.6 | 10 | 18 | 32  | 56  |
| Mortality [%] | 96       | 0                            | 5   | 0   | 0  | 15 | 100 | 100 |
| Symptoms*     | 24-96    |                              |     |     |    | +  |     |     |

\*Symptoms included twitching, quiescent, dark discolored, gulping air and/or labored.

**Conclusion** The 96-h LC<sub>50</sub> calculated by the author using trimmed SPK was 22 mg/L (95% CI 20-24 mg/L) ⇔ 20 mg a.i./L (95% CI 18-22 mg/L).

**Klimisch criterium** 2 Static test with no chemical analyses performed; non-GLP study.

### Acute Toxicity to Aquatic Invertebrates

#### Daphnia:

#### 9.3.07

|                       |   |  |
|-----------------------|---|--|
| <b>Title</b>          | Static acute toxicity of CASRN 26264-05-1 to <i>Daphnia magna</i>                   |  |
| <b>Date of report</b> | May 8, 2000.  |  |
| <b>GLP</b>            | No.   |  |
| <b>Reference</b>      | 24  |  |
| <b>Test substance</b> | A (Benzenesulfonic acid, dodecyl-, compd. with isopropylamine (1:1)), purity 89.4%. |  |
| <b>Test method</b>    | OECD 202.   |  |
| <b>Stat. method</b>   | None.   |  |
| <b>Test system</b>    | <b>Species</b>  | <i>Daphnia magna</i> , <24 h old.  |
|                       | <b>No. of daphnids</b>  | 5/replicate, 4 replicates/treatment.   |
|                       | <b>Concentrations</b>   | Nominal: 1.56, 3.13, 6.25, 12.5, 25, 50 and 100 mg/L (no vehicle), untreated controls.   |
|                       | <b>Test conditions</b>  | Static; at 20±2°C in 225 mL crystallising dishes (covered), containing 100 mL of reconstituted water of hardness 168 mg/l (CaCO <sub>3</sub> ) and pH 8.3, 16 h light. |
|                       | <b>Phys. meas.</b>  | At 0 and 48 h in one replicate for all concentrations; overall ranges for pH 8.4-8.5; O <sub>2</sub> 91-97%; temperature (0, 24 and 48 h) 20-21°C.                     |
|                       | <b>Observations</b>   | Immobility/mortality at 24 and 48 h.   |

## Results

| Parameter      | Time [h] | Nominal concentration [mg/L] |      |      |      |      |     |     |     |
|----------------|----------|------------------------------|------|------|------|------|-----|-----|-----|
|                |          | 0                            | 1.56 | 3.13 | 6.25 | 12.5 | 25  | 50  | 100 |
| Immobility [%] | 48       | 0                            | 0    | 85   | 100  | 100  | 100 | 100 | 100 |

**Conclusion** The 48-h EC<sub>50</sub> calculated by the author using trimmed SPK was 2.5 mg/L (95% CI 2.2-2.7 mg/L) ⇔ 2.2 mg a.i./L (95% CI 2.0-2.4 mg a.i./L).

**Klimisch criterium** 2 Static test with no chemical analyses were performed; non-GLP study.

### 9.3.26

**Title** Toxicity of a linear alkylate sulfonate detergent to larvae of four species of freshwater fish

**Date of report** 1975.

**GLP** No data

**Reference** 14

**Test substance** 2 (Benzenesulphonic acid, linear alkyl); commercial detergent formulation containing 14% LAS; 2.3% alcoholethoxylate oxide condensate; 2.5% sodium soap; 48% sodium tripolyphosphate; 9.7% sodium silicate; 15.4% sodium sulphate; 8.1% moisture and miscellaneous.

**Guideline** Not indicated.

**Stat. method** One-way analysis of variance (Dunnett 1955).

**Test system** **Species** Northern pike (*Esox lucius*); White sucker (*Catostomus commersoni*); Smallmouth bass (*Micropterus dolomieu*); Fathead minnow (*Pimephales promelas*); 2-3 days after hatching.

**No. of fish** 50/test vessel (2 vessel/treatment) for Northern pike and White sucker; 25/test vessel (2 vessel/treatment) for Smallmouth bass; 15/test vessel (2 vessel/treatment) for Fathead minnow.

**Concentrations** 0.2-0.3, 0.5, 1.1-1.2, 2.3-2.6 and 5.0-6.3 mg/L MBAS (apprx. equivalent to LAS); untreated controls.

**Test conditions** 30-day flow-through (no aeration) in tanks containing 12.5 L of lake water (hardness 36-48 mg/L as CaCO<sub>3</sub>), 6 replacements/24 h, temperature 15±1°C, except for *Pimephales promelas* 23±1°C; feeding at least twice daily.

**Analysis** Once a week for all concentrations (composite of daily taken samples) using the MBAS-procedure after preservation with 1% formaldehyde (ref. standard 4.045% aqueous LAS).

**Phys. meas.** One tank per week: overall ranges for pH 7.2-7.9; overall ranges O<sub>2</sub> 5.6-10 mg/L.

**Observations** Mortality; body weight (total = standing crop) on day 30.

**Results** For analytical results see 1<sup>st</sup> table below. Biological data are shown in the 2<sup>nd</sup> table. QCs were completely recoverable.

#### Analysis

| Test chamber | Measured concentration ± standard error (mg/L) |                      |                    |                    |
|--------------|--|----------------------|--------------------|--------------------|
|              | <i>E. lucius</i>                               | <i>C. commersoni</i> | <i>M. dolomieu</i> | <i>P. promelas</i> |
| 1            | 5.9 ± 0.2                                      | 5.0 ± 0.3            | 6.3 ± 0.05         | 5.8 ± 0.35         |
| 2            | 2.4 ± 0.1                                      | 2.6 ± 0.15           | 2.5 ± 0.05         | 2.3 ± 0.05         |
| 3            | 1.2 ± 0.05                                     | 1.1 ± 0.10           | 1.2 ± 0.05         | 1.2 ± 0.05         |
| 4            | 0.5 ± 0.05                                     | 0.5 ± 0.05           | 0.5 ± 0.05         | 0.5 ± 0.01         |
| 5            | 0.3 ± 0.01                                     | 0.2 ± 0.01           | 0.3 ± 0.01         | 0.2 ± 0.05         |
| Control      | 0.02 ± 0.005                                   | 0.01 ± 0.005         | 0.02 ± 0.005       | 0.02 ± 0.01        |
|              |  |                      |                    |                    |

### Biological

| Parameter                          | Time [d] | Mean measured concentration [mg/L] |         |     |         |         |         |
|------------------------------------|----------|------------------------------------|---------|-----|---------|---------|---------|
|                                    |          | 0                                  | 0.2-0.3 | 0.5 | 1.1-1.2 | 2.3-2.6 | 5.0-6.3 |
| Standing crop* <i>E. lucius</i>    | 30       | I                                  | i       | dc  | dc      | -       |         |
| Standing crop <i>C. commersoni</i> | 30       | Dc                                 | dc      | dc  | dc      | dc      |         |
| Standing crop <i>M. dolomieu</i>   | 30       | lc                                 | ic      | ic  | lc      | dc      |         |
| Standing crop <i>P. promelas</i>   | 30       | =                                  | d       | dc  | dc      | -       |         |

\* Standing crop: the biomass of a particular area, ecosystem etc. at any specified time. d=decrease, I=increase, c=significant

**Conclusions**

*Esox lucius* : 96-h LC50 3.7 mg/L; 30-d NOEC 0.6 mg/L  
*Catostomus commersoni* : 96-h LC50 4.0 mg/L; 30-d NOEC ~0.2 mg/L  
*Micropterus dolomieu* : 96-h LC50 3.7 mg/L; 30-d NOEC 3 mg/L  
*Pimephales promelas* : 96-h LC50 3.4 mg/L; 30-d NOEC 0.5 mg/L

**Rev. note**

30-day NOEC based on standing crop

1. Because the test substance is a formulation, the observed toxicity reflects exposure to LAS and the other components. Nominal concentrations were not reported, so mean measured concentrations have been used in this summary. From the report it is not completely clear whether concentrations are expressed in mg formulation or mg active ingredient. It is assumed that concentrations are expressed in mg active ingredient (i.e., LAS) and this is consistent with the MBAS analytical measurement.
2. Observations were made for the dead of juvenile fish, but mortality is not reported. The LC50 values included in the conclusions could not be checked with the original data.

**Klimisch criterium**

2 Incomplete description (notes 1 & 2).

### 9.3.27

**Title** Terrestrial safety assessment of linear alkylbenzene sulfonate  
**Date of report** 1990.  
**GLP** No.  
**Reference** 16  
**Test substance** 2 (Benzenesulphonic acid, linear alkyl), LAS C<sub>10-13</sub>, mean 11.6.  
**Test method** OECD 208 (1984).  
**Stat. method** Not indicated.  
**Test system**

**Species** Sorghum (*Sorghum bicolor*)  
Sunflower (*Helianthus annuus*)  
Mung bean (*Phaseolus aureus*)

**No. of seeds** 8 seeds/pot, 4 pots/treatment.

**Procedure** The test was performed in a greenhouse at 20°C with 14 h light in non-porous plastic plant pots (Ø 10 cm) containing 600 g soil (mixture of grit, loam and fertilizer). A premix was prepared from silver sand and a solution of LAS in water. The premix was blended with the soil (1:9). The treatment rates were 1, 10, 100 and 1000 mg a.i./kg dry soil. Untreated controls were included for sorghum.

**Observations** Emergence on day 7.  
Growth on day 21.

**Conclusion**

Sorghum: Emergence [%] was 64-78% for 0-1000 mg/kg;  
21-d EC<sub>50,growth</sub> 167 mg/kg.  
Sunflower: Emergence [%] was >91% for 1-1000 mg/kg soil ;  
21-d EC<sub>50,growth</sub> 289 mg/kg.  
Mung bean: Emergence [%] was ≥75% for 1-1000 mg/kg soil;  
21-d EC<sub>50,growth</sub> 316 mg/kg.  
21-d NOEC<sub>growth</sub> 100 mg/kg for all species

**Rev. note**

The information was essentially confined to what is included in the above summary. On the basis of the limited information provided, checking of compliance with guideline



**Klimisch  
criterium**

requirements was only possible to a limited extent. The determination of the effect concentrations (NOEC and EC50) for growth cannot be checked by individual data.  
2 Incomplete description.

**9.3.28**

**Title** Terrestrial safety assessment of linear alkylbenzene sulfonate  
**Date of report** 1990.  
**GLP** No.  
**Reference** 16  
**Test substance** 2 (Benzenesulphonic acid, linear alkyl), LAS C<sub>10-13</sub>, mean 11.6.  
**Test method** OECD 207 (1984).  
**Stat. method** Not indicated.  
**Test system** **Species** Earthworm (*Eisenia foetida*), mean weight 660 mg.  
**No. of worms** 10 worms/jar, 4 jars/treatment.  
**Procedure** The test was performed at 20±2°C under continuous illumination in 0.9 L glass jars, containing 900 g of wet artificial soil (peat/clay/sand: 10/20/70%). An aqueous solution of LAS was added to the soil. The treatment rates were 63, 125, 250, 500, and 1000 mg/kg soil. Untreated controls were included. Moisture level was maintained at 35±1%.  
**Observations** Mortality, symptoms, body weight on day 7 and 14.  
**Analysis** At 250 mg/kg by HPLC.  
**Results** Reductions in body weights of respectively 14, 33 and 23% were observed at 0, 100 and 500 mg/kg.  
Measured concentration was 94% of nominal.

| Parameter     | Time [d] | Nominal concentration [mg/kg soil] |    |     |     |     |      |
|---------------|----------|------------------------------------|----|-----|-----|-----|------|
|               |          | 0                                  | 63 | 125 | 250 | 500 | 1000 |
| Mortality [%] | 14       | 0                                  | 0  | 0   | 0   | 0   | 5    |

**Conclusions** 14-day LC<sub>50</sub> >1000 mg/kg  
**Rev. note** 1. No positive control included.  
**Klimisch criterium** 2 No positive control; non-GLP study

## Appendix 9-4 - Health Data for LAS/ABS

### Acute Toxicity:

#### Oral:

##### 9.4.01

**Title** MSDS Rhodacal® 330  
**Date of report** May 14, 1999.  
**GLP** No data  
**Reference** 22  
**Test substance** A (Benzenesulfonic acid, dodecyl-, compd. With isopropylamine (1:1)), purity 90%.  
**Guideline** Not specified.  
**Toxicity** LD50-rat 1836 mg/kg.  
**Klimisch criterium** 4 – Secondary literature

##### 9.4.02

**Title** Defined oral LD<sub>50</sub>  
**Date of report** October 8, 1980.  
**GLP** No data  
**Reference** 32  
**Test substance** A (Benzenesulfonic acid, dodecyl-, compd. With isopropylamine (1:1)), purity 90.9%.  
**Guideline** Defined oral LD50. Adapted from appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics, by the Association of Food and Drug Officials of the United States, 1965.  
**Stat. method** Litchfield-Wilcoxin (Probit analysis).  
**Test system** **Species** Rat (Sprague-Dawley), weight 200-300 g.  
**No. of animals** 5/sex/dose group.  
**Dosage** Single dose by oral gavage of 1.0, 1.5, 2.0, 2.5 and 3.0 mL/kg bw.  
**Observations** Mortality/clinical signs daily for 14 days.  
 Body weight on day 0 and 14.  
 Macroscopy on animals that died.

#### Results

| Dose [mL kg bw] \ effect<br>Sex | Day  | 1.0                          |     | 1.5 |     | 2.0 |     | 2.5 |     | 3.0 |     | DR |   |
|---------------------------------|------|------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|---|
|                                 |      | M                            | F   | M   | F   | M   | F   | M   | F   | M   | F   | M  | F |
| Mortality                       | 0-14 |                              | 1/5 |     | 4/5 |     | 4/5 | 3/5 | 5/5 | 5/5 | 5/5 | x  | x |
| Body weight gain survivors      | 0-14 | No treatment related effects |     |     |     |     |     |     |     | N/A | N/A |    |   |
| Clinical signs                  | 0-14 | No treatment related effects |     |     |     |     |     |     |     |     |     |    |   |
| Necropsy <sup>(A)</sup>         |      |                              |     |     | +   |     | +   | +   | +   | +   | +   |    |   |

(A) Pulmonary haemorrhage among animals that died.

**Conclusions** Oral LD<sub>50</sub> 1.8 ml/kg bw. which is equivalent to 1300 mg/kg bw  
**Klimisch criterium** 2 Only partial report available.

##### 9.4.03

**Title** Acute oral toxicity studies with ten samples in albino rats  
**Date of report** May 29, 1973.  
**GLP** No.  
**Reference** 9  
**Test substance** B (Benzenesulfonic acid, dodecyl-, compd. With 2,2',2''-nitrilotris(ethanol)(1:1)), purity 25%.  
**Guideline** Not indicated.  
**Test system** **Species** Rat.  
**No. of animals** Not indicated.  
**Dosage/observations** Not indicated.  
**Stat. method** Weil, Thompson.

|                           |  |
|---------------------------|--|
| <b>Results</b>            | Limited to LD <sub>50</sub> -value.              |
| <b>Conclusions</b>        | Oral LD <sub>50</sub> 1653 (±238) mg a.i./kg bw. |
| <b>Rev. note</b>          | Only select pages of the report were available.  |
| <b>Klimisch criterium</b> | 4 Incomplete report.                             |

#### 9.4.04

|                           |   |  |
|---------------------------|---|--|
| <b>Title</b>              | Final report on the safety assessment of sodium dodecylbenzenesulfonate/TEA-dodecylbenzenesulfonate/sodiumdecylbenzenesulfonate |  |
| <b>Date of report</b>     | 1997.   |  |
| <b>GLP</b>                | No data   |  |
| <b>Reference</b>          | 1   |  |
| <b>Test substance</b>     | B, Benzenesulfonic acid, dodecyl-, compd. With 2,2',2''-nitritoltris(ethanol) (1:1).  |  |
| <b>Guideline</b>          | Not indicated.  |  |
| <b>Stat. method</b>       | Not applicable.   |  |
| <b>Test system</b>        | <b>Species</b>  | Rat (Sprague-Dawley).  |
|                           | <b>No. of animals</b>   | 5/sex/dose group.  |
|                           | <b>Dosage</b>   | Single oral administration of 91, 195, 420, 906 and 1953 mg/kg bw (vehicle water, dosing volume 0.464-10 ml/kg). |
|                           | <b>Observations</b>   | Mortality/clinical signs during 14 days.<br>Necropsy on day 14.  |
| <b>Results</b>            | No deaths, diarrhea among animals.  |  |
| <b>Conclusions</b>        | Oral LD <sub>50</sub> >10 ml/kg bw ⇔ >1953 mg/kg bw.  |  |
| <b>Rev. note</b>          | The report was limited to the above mentioned.  |  |
| <b>Klimisch criterium</b> | 2 A CTFA Cosmetic Ingredient Review   |  |

#### 9.4.05

|                           |   |
|---------------------------|---|
| <b>Title</b>              | MSDS Rhodacal® CA/70  |
| <b>Date of report</b>     | August 17, 1999.  |
| <b>GLP</b>                | No data   |
| <b>Reference</b>          | 21  |
| <b>Test substance</b>     | C (Benzenesulfonic acid, dodecyl-,calcium salt), purity 69-71%. |
| <b>Guideline</b>          | Not specified.  |
| <b>Toxicity</b>           | LD50-rat 1.8 mL/kg ⇔ 1.3 g a.i./kg = 1300 mg/kg bw              |
| <b>Klimisch criterium</b> | 4 - Secondary literature  |

#### 9.4.06

|                       |   |   |
|-----------------------|---|---|
| <b>Title</b>          | Akute orale Toxizität von Marlon A 386 für Ratten   |   |
| <b>Date of report</b> | February 15, 1984.  |   |
| <b>GLP</b>            | No data   |   |
| <b>Reference</b>      | 15  |   |
| <b>Test substance</b> | D (Benzenesulfonic acid, dodecyl-, branched) or 1 (Benzenesulfonic acid, mono-C11-13-branched alkyl) or 4 (Benzenesulfonic acid, linear alkyl), purity 86%. |   |
| <b>Guideline</b>      | OECD 401.   |   |
| <b>Stat. method</b>   | Lichtfield and Wilcoxon.  |   |
| <b>Test system</b>    | <b>Species</b>  | Rat (Bor: WISW), mean weight 123-146 g.   |
|                       | <b>No. of animals</b>   | 5/sex/dose group.   |
|                       | <b>Dosage</b>   | Single oral administration of 1250, 1415, 1580 and 1990 mg/kg bw (vehicle water, dosing volume 10 ml/kg); no controls; feeding <i>ad libitum</i> (food was withheld ~16 h prior to dosing). |
|                       | <b>Observations</b>   | Mortality/clinical signs several times during the first 6 h and daily until day 14.<br>Body weights on day 0, 1, 7 and 14.<br>Necropsy on day 14.   |

## Results

| Dose [mg a.i./kg bw] \ effect |      | 1250                         |     | 1415 |     | 1580 |     | 1990 |     | DR |   |
|-------------------------------|------|------------------------------|-----|------|-----|------|-----|------|-----|----|---|
| Sex                           | Day  | M                            | F   | M    | F   | M    | F   | M    | F   | M  | F |
| Mortality                     | 1-14 | 0/5                          | 4/5 | 5/5  | 3/5 | 4/5  | 5/5 | 5/5  | 5/5 |    |   |
| Clinical signs <sup>(A)</sup> | 1-14 | +                            | +   | +    | +   | +    | +   | +    | +   |    |   |
| Body weight gain              | 1-15 | No treatment related effects |     |      |     |      |     |      |     |    |   |
| Necropsy <sup>(B)</sup>       | 15   | +                            |     | +    |     | +    |     | +    |     |    |   |

(A) Clinical observations included piloerection, hunched posture, diarrhoea, difficult respiration, nasal bleedings, uncoordinated movements, ataxia and (minor) sedation during day 1-5.

(B) Findings consisted of redness of the mucous membrane of the stomach and intestine, hyperaemia of the stomach, adhesions in stomach, liver, spleen and kidneys with peritoneum.

**Conclusions** Oral LD<sub>50</sub> 1260 mg/kg bw ⇔ 1080 mg a.i./kg bw (95% C.I. 970-1210 mg a.i./kg bw).

**Klimisch criterium** 2 non-GLP study

### 9.4.07

**Title** Toxicologic studies with branched and linear alkyl benzene sulfonates in rats  
**Date of report** 1965.  
**GLP** No data  
**Reference** 17  
**Test substance** E (Benzenesulfonic acid, mono-C11-13-branched alkyl derivs.) (C<sub>10</sub>-C<sub>14</sub>), purity 87.1% (sodium sulfate 10.5%, water 2.2 %, oil 0.9%).  
**Guideline** Hagan (1959).  
**Stat. method** Calculation by method of Miller and Tainter.  
**Test system** **Species** Rat (FDRL(Wistar)).  
**No. of animals** 3/sex/dose group.  
**Procedure** Single dose by oral gavage (10% dispersion in water).  
**Observations** Mortality/clinical signs at least daily during 14 days after dosing;  
Body weights on day 0, 7 and 14;  
Necropsy on day 14 or on day of death.  
**Conclusions** Oral LD<sub>50</sub> 520 mg a.i./kg bw.  
**Klimisch criterium** 2 Older study; published but no lab report

### 9.4.15

**Title** Toxicologic studies with branched and linear alkyl benzene sulfonates in rats  
**Date of report** 1965.  
**GLP** No data  
**Reference** 17  
**Test substance** 2 (Benzenesulphonic acid, linear alkyl) (C<sub>9</sub>-C<sub>15</sub>), purity 39.5% (sodium sulphate 8.8%, water 50.9 %, free alkali (NaOH) 0.05%, unidentified 0.64%).  
**Guideline** Hagan (1959).  
**Stat. method** Calculation by method of Miller and Tainter.  
**Test system** **Species** Rat (FDRL(Wistar)).  
**No. of animals** 3/sex/dose group.  
**Procedure** Single dose by oral gavage (10% dispersion in water).  
**Observations** Mortality/clinical signs at least daily during 14 days after dosing;  
Body weights on day 0, 7 and 14;  
Necropsy on day 14 or on day of death.  
**Conclusions** Oral LD<sub>50</sub> 650 mg a.i./kg bw.  
**Rev. note** 1. No individual data were presented.  
2. Equivalent doses as 10 and 40% dispersion were given at 600 and 1580 mg/kg. Mortality was not affected by the use of a more concentrated suspension, but a higher incidence of diarrhoea was noted at the most concentrated suspension.  
**Klimisch criterium** 2 Limited report, non-GLP study.

### **Dermal:**

#### **9.4.16**

**Title** Final report on the safety assessment of sodium dodecylbenzenesulfonate/TEA-dodecylbenzenesulfonate/sodiumdecylbenzenesulfonate

**Date of report** 1997.

**GLP** No data

**Reference** 1

**Test substance** B, Benzenesulfonic acid, dodecyl-, compd. with 2,2',2''-nitrilotris(ethanol) (1:1).

**Guideline** Not indicated.

**Stat. method** Not applicable.

**Test system** **Species** Rabbit (New Zealand White).  
**No. of animals** 8.  
**Dosage** Single application of 4199 mg/kg bw (vehicle water) to the clipped skin under occlusion for 24 hours..  
**Observations** Mortality/clinical signs during 14 days.  
Necropsy on day 14.

**Results** No deaths, diarrhea and emaciation in two animals, erythema.

**Conclusions** Dermal LD<sub>50</sub> >21.5 ml/kg bw ⇔ >4199 mg/kg bw.

**Klimisch criterium** 2 - CTFA Cosmetic Ingredient Review

### **Irritation and Sensitization:**

#### **9.4.21**

**Title** Primary skin irritation

**Date of report** September 18, 1980.

**GLP** No data

**Reference** 31

**Test substance** A (Benzenesulfonic acid, dodecyl-, compd. with isopropylamine (1:1)), purity 90.9%.

**Guideline** FHSLA 16 CFR 1500.

**Stat. method** Not applicable.

**Test system** **Species** Rabbit (New Zealand White).  
**No. of animals** 6 (sex not indicated)  
**Dosage** Application of 0.5 ml test substance (no vehicle) on ~6.25 cm<sup>2</sup> of the clipped skin (intact and abraded) under semi-occlusion for 24 hours.  
**Observations** Skin observations at 24 and 72 h after application.

#### **Results**

|      | Mean score |        |
|------|------------|--------|
| Time | Erythema   | Oedema |
| 24 h | 1.83       | 2.33   |
| 72 h | 3.00       | 1.67   |

E=erythema

O=oedema

#### **Conclusions**

Irritating.

#### **Rev. note**

1. The application time was 24 h, which is considered to be a worst case situation (OECD 404, 4 h application).

#### **Klimisch criterium**

4 - Only an incomplete lab report available

#### **9.4.22**

**Title** D.O.T. corrosivity study (Modified)

**Date of report** September 13, 1993.

**GLP** No (Quality Assurance Statement included).

**Reference** 11

**Test substance** *Test 1:* B (Benzenesulfonic acid, dodecyl-, compd. with 2,2',2''-nitrilotris(ethanol)(1:1)), purity 60% (40% water), *Test 2:* D (Benzenesulfonic acid, dodecyl-, branched) or 1 (Benzenesulfonic acid, mono-C11-13-branched alkyl), purity 93-95% (1% sulfuric acid, 0.7% water).

**Guideline** Not indicated.  
**Test system** Species Rabbit (New Zealand White), 8-10 weeks old.  
 No. of animals 3 (sex not indicated).  
 Dosage Application of 0.5 g test substance on the skin under occlusion for 4 hours.  
 Observations Skin observations at 4, 24, 48 and 72 h after application.

**Stat. Method** Not applicable.

**Results** *Test 1*

| Animal | 1 |   | 2 |   | 3 |   |
|--------|---|---|---|---|---|---|
| Time   | E | O | E | O | E | O |
| 4 h    | 1 | 1 | 1 | 1 | 1 | 1 |
| 24 h   | 2 | 2 | 1 | 1 | 3 | 2 |
| 48 h   | 3 | 2 | 3 | 2 | 3 | 2 |
| 72 h   | 3 | 2 | 3 | 1 | 3 | 2 |

E=erythema

O=oedema

**Conclusion** Irritating

**Results** *Test 2*

| Animal | 1 |   | 2 |   | 3 |   |
|--------|---|---|---|---|---|---|
| Time   | E | O | E | O | E | O |
| 4 h    | 1 | 1 | 1 | 2 | 1 | 1 |
| 24 h   | 2 | 2 | 2 | 2 | 2 | 2 |
| 48 h   | 2 | 1 | 3 | 2 | 3 | 2 |
| 72 h   | 2 | 1 | 2 | 2 | 3 | 2 |

E=erythema

O=oedema

**Conclusion** Irritating.

**Rev. note** 1. The test was performed with occlusive dressing. This is considered to represent a worst case situation, since the occlusion is expected to increase penetration through the skin.

**Klimisch criterium** 1

#### 9.4.23

**Title** MSDS Rhodacal® CA/70  
**Date of report** August 17, 1999.  
**GLP** No data  
**Reference** 21  
**Test substance** C (Benzenesulfonic acid, dodecyl-,calcium salt), purity 69-71%.  
**Guideline** Not specified.  
**Skin irritation** Moderately irritating in rabbit.  
**Klimisch criterium** 4 - Secondary literature

#### 9.4.24

**Title** D.O.T. corrosivity study (Modified)  
**Date of report** April 21, 1993.  
**GLP** No (Quality Assurance Statement included).  
**Reference** 13  
**Test substance** E (Benzenesulfonic acid, mono-C11-13-branched alkyl derivs.), purity 96% (2% sulfuric acid, 2% benzene (tetrapropenyl derivs)).  
**Guideline** Not indicated.  
**Test system** **Species** Rabbit (New Zealand White), 8-10 weeks old.  
**No. of animals** 3 (sex not indicated).  
**Dosage** Application of 0.5 g test substance on the skin under occlusion for 4 hours.  
**Observations** Skin observations at 4, 24, 48 and 72 h after application.  
**Stat. Method** Not applicable.

**Results** *Test 1 (90% solution in distilled water)*

| Animal | 1 |   | 2 |   | 3 |   |
|--------|---|---|---|---|---|---|
| Time   | E | O | E | O | E | O |
| 4 h    | 4 | 2 | 4 | 2 | 3 | 2 |
| 24 h   | 4 | 2 | 4 | 1 | 4 | 1 |
| 48 h   | 4 | 1 | 4 | 1 | 4 | 1 |
| 72 h   | 4 | 1 | 4 | 1 | 4 | 1 |

E=erythema

O=oedema

**Conclusion**

Irritating

**Results** *Test 2 (60% solution in distilled water)*

| Animal | 1 |   | 2 |   | 3 |   |
|--------|---|---|---|---|---|---|
| Time   | E | O | E | O | E | O |
| 4 h    | 3 | 1 | 4 | 1 | 2 | 1 |
| 24 h   | 4 | 1 | 4 | 1 | 3 | 1 |
| 48 h   | 4 | 1 | 4 | 1 | 3 | 1 |
| 72 h   | 4 | 1 | 4 | 1 | 4 | 1 |

E=erythema

O=oedema

**Conclusion**

Irritating.

**Results** *Test 3 (30% solution in distilled water)*

| Animal | 1 |   | 2 |   | 3 |   |
|--------|---|---|---|---|---|---|
| Time   | E | O | E | O | E | O |
| 4 h    | 1 | 0 | 2 | 1 | 2 | 2 |
| 24 h   | 2 | 1 | 2 | 1 | 2 | 1 |
| 48 h   | 2 | 1 | 2 | 1 | 3 | 1 |
| 72 h   | 3 | 1 | 3 | 1 | 3 | 1 |

E=erythema

O=oedema

**Conclusion**

Irritating.

**Rev. note**

- The test was performed with occlusive dressing. This is considered to represent a worst case situation, since the occlusion is expected to increase penetration through the skin.

**Klimisch criterium**

1

**9.4.25****Title** D.O.T. corrosivity study (Modified)**Date of report** March 13, 1993.**GLP** No. (Quality Assurance Statement included)**Reference** 12**Test substance** E (Benzenesulfonic acid, mono-C11-13-branched alkyl), purity 96% (2% sulfuric acid, 2% benzene (tetrapropenyl derivs.)).**Guideline** Not indicated.**Test system** **Species** Rabbit (New Zealand White), 8-10 weeks old.**No. of animals** 3 (sex not indicated).**Dosage** Application of 0.5 g test substance on the skin under occlusion for 4 hours.**Observations** Skin observations at 4, 24, 48 and 72 h after application.**Stat. method**

Not applicable.

**Results**

| Animal | 1 |   | 2 |   | 3 |   |
|--------|---|---|---|---|---|---|
| Time   | E | O | E | O | E | O |
| 4 h    | 2 | 2 | 2 | 2 | 1 | 1 |
| 24 h   | 2 | 2 | 3 | 3 | 2 | 2 |
| 48 h   | 2 | 2 | 3 | 3 | 2 | 2 |
| 72 h   | 3 | 3 | 3 | 3 | 3 | 3 |

E=erythema

O=oedema

**Conclusion**

Irritating.

**Rev. note** 1. The test was performed with occlusive dressing. This is considered to represent a worst case situation, since the occlusion is expected to increase penetration through the skin.

**Klimisch criterium** 1

#### 9.4.30

**Title** Modified eye irritation

**Date of report** September 30, 1980.

**GLP** No data

**Reference** 23

**Test substance** A (Benzenesulfonic acid, dodecyl-, compd. with isopropylamine (1:1)), purity 90.9%.

**Guideline** EPA 40 CFR 163.81-4

**Test system** **Species** Rabbit (New Zealand White).

**No. of animals** 3 (with rinsing) and 6 (without rinsing), sex not indicated.

**Dosage** Application of 0.1 ml test substance in the eye. For 3 animals eyes were rinsed with water 30 seconds after instillation.

**Observations** Observations at 24, 48 and 72 h and on day 4 and 7 after application.

**Stat. method** Not applicable.

#### Results

Test with rinsing

| Animal | 1 |   |      |    | 2 |   |      |    | 3 |   |      |    |
|--------|---|---|------|----|---|---|------|----|---|---|------|----|
| Effect | C | I | Conj |    | C | I | Conj |    | C | I | Conj |    |
| Time   |   |   | Red  | Ch |   |   | Red  | Ch |   |   | Red  | Ch |
| 24 h   | 2 | 0 | 2    | 2  | 2 | 0 | 2    | 3  | 2 | 0 | 2    | 4  |
| 48 h   | 2 | 0 | 2    | 3  | 2 | 0 | 2    | 4  | 2 | 1 | 2    | 4  |
| 72 h   | 2 | 1 | 1    | 3  | 2 | 0 | 2    | 3  | 3 | 1 | 2    | 4  |
| 4 d    | 1 | 1 | 1    | 2  | 2 | 0 | 3    | 3  | 2 | 1 | 2    | 3  |
| 7 d    | 2 | 1 | 0    | 1  | 2 | 0 | 1    | 2  | 3 | 1 | 2    | 3  |

Test without rinsing

| Animal | 1 |   |      |    | 2 |   |      |    | 3 |   |      |    | 4 |   |      |    | 5 |   |      |    | 6 |   |      |    |
|--------|---|---|------|----|---|---|------|----|---|---|------|----|---|---|------|----|---|---|------|----|---|---|------|----|
| Effect | C | I | Conj |    | C | I | Conj |    | C | I | Conj |    | C | I | Conj |    | C | I | Conj |    | C | I | Conj |    |
| Time   |   |   | Red  | Ch |   |   | Red  | Ch |   |   | Red  | Ch |   |   | Red  | Ch |   |   | Red  | Ch |   |   | Red  | Ch |
| 24 h   | 3 | 1 | 2    | 3  | 2 | 0 | 2    | 4  | 2 | 1 | 2    | 4  | 2 | 0 | 2    | 4  | 2 | 0 | 2    | 3  | 3 | 0 | 0    | 4  |
| 48 h   | 3 | 1 | 2    | 3  | 2 | 0 | 1    | 4  | 3 | 0 | 1    | 4  | 2 | 0 | 1    | 3  | 2 | 0 | 2    | 3  | 2 | 0 | 1    | 4  |
| 72 h   | 3 | 1 | 2    | 4  | 2 | 0 | 1    | 4  | 4 | 2 | 1    | 4  | 2 | 1 | 1    | 2  | 2 | 0 | 2    | 4  | 2 | 1 | 1    | 3  |
| 4 d    | 3 | 0 | 2    | 1  | 2 | 0 | 1    | 2  | 2 | 1 | 1    | 3  | 1 | 0 | 1    | 0  | 1 | 1 | 2    | 3  | 2 | 1 | 1    | 1  |
| 7 d    | 3 | 0 | 1    | 3  | 3 | 1 | 1    | 3  | 3 | 1 | 0    | 3  | 2 | 0 | 0    | 0  | 2 | 1 | 1    | 2  | 3 | 1 | 1    | 2  |

C=corneal opacity I=Iris Conj=conjunctiva Red=redness Ch=chemosis

**Conclusion** Irritating

**Klimisch criterium** 2 Non-GLP study

#### 9.4.31

**Title** MSDS Rhodacal® CA/70

**Date of report** August 17, 1999.

**GLP** No.

**Reference** 21

**Test substance** C (Benzenesulfonic acid, dodecyl-,calcium salt), purity 69-71%.

**Guideline** Not specified.

**Eye irritation** Severely irritating in rabbit.

**Klimisch criterium** 4 - Secondary literature



## Genetic Toxicity *in vitro*:

### 9.4.38

|                       |  |  |
|-----------------------|--|--|
| <b>Title</b>          | Studies of <i>in vitro</i> cell transformation and mutagenicity by surfactants and other compounds   |  |
| <b>Date of report</b> | 1979.  |  |
| <b>GLP</b>            | No.  |  |
| <b>Reference</b>      | 6  |  |
| <b>Test substance</b> | 2 (Benzenesulphonic acid, linear alkyl), C <sub>10</sub> -C <sub>14</sub> , purity 22% active (0.033% alkylbenzene, 0.02% NaSO <sub>4</sub> ). |  |
| <b>Guideline</b>      | Not indicated.   |  |
| <b>Stat. method</b>   | Not indicated.   |  |
| <b>Test system</b>    | <b>Cell culture</b>  | Syrian golden hamster embryo cells.  |
|                       | <b>Test concentration</b>  | 5, 10, 20 and 50 µg/ml.<br>0.5, 1, 5 and 10 µg/ml.   |
|                       | <b>Controls</b>  | <u>Negative</u> : vehicle (DMSO).<br><u>Positive</u> : 3-methylcholanthrene  |
|                       | <b>Procedure</b>   | Pregnant Syrian golden hamsters were killed on day 13 or 14 of gestation. Embryos were minced and trypsinised and cells were cryopreserved. Unthawed cells were plated twice (as feeder-layer and target cells) on day 0 and 3 resp.. On day 4 feeder-layer cells were plated (after irradiation and trypsinisation) at 6x10 <sup>4</sup> cells/dish and on day 5 500 target cells/dish were added to the dishes. On day 6 the test substance was added. On day 14 cultures were fixed and stained and normal and transformed colonies were counted. |

**Results** Positive control negative.

| Doses tested [µg/ml] | Cytotoxicity [% of control survival] at highest dose | Test result <sup>(A)</sup> |
|----------------------|--|----------------------------|
| 5, 10, 20, 50        | 40%  | -                          |
| 0.5, 1, 5, 10        | 88%  | -                          |

(A) +/- : positive/negative result.

|                           |   |
|---------------------------|---|
| <b>Conclusion</b>         | Not mutagenic.  |
| <b>Rev. note</b>          | 1. The results of a simultaneously performed test with the positive control (at 0.1, 0.5 and 1.0 µg/ml) were negative. This lowers the value of the assay |
| <b>Klimisch criterium</b> | 4 Positive control was negative; secondary literature.  |

### 9.4.39

|                       |  |   |
|-----------------------|--|---|
| <b>Title</b>          | Studies of <i>in vitro</i> cell transformation and mutagenicity by surfactants and other compounds   |   |
| <b>Date of report</b> | 1979.  |   |
| <b>GLP</b>            | No.  |   |
| <b>Reference</b>      | 6  |   |
| <b>Test substance</b> | 2 (Benzenesulphonic acid, linear alkyl), C <sub>10</sub> -C <sub>14</sub> , purity 22% active (0.033% alkylbenzene, 0.02% NaSO <sub>4</sub> ). |   |
| <b>Guideline</b>      | Not indicated  |   |
| <b>Stat. method</b>   | Not indicated.   |   |
| <b>Test system</b>    | <b>Bacterial strains</b>   | TA98, TA100.  |
|                       | <b>Metabolic activation</b>  | Rat liver S9 mix (polychlorinated biphenyl-induced).  |
|                       | <b>Test concentration</b>  | 10, 25, 50, 100 and 200 µg/plate.   |
|                       | <b>Controls</b>  | <u>Negative</u> : vehicle (DMSO or water not specified).<br><u>Positive</u> : 4-nitroquinoline 1 oxide, <i>N</i> -methyl- <i>N</i> -nitro- <i>N</i> -nitrosoguanidine, benzo[a]pyrene, 2-acetylaminofluorene, <i>N</i> -nitrosomethylamine. |
|                       | <b>Procedure</b>   | According to OECD 471.  |

**Results**

| Tester strain | Test result <sup>(A)</sup> |                 |
|---------------|----------------------------|-----------------|
|               | Without activation         | With activation |
| TA98          | -                          | -               |
| TA100         | -                          | -               |

(A) +/- : positive/negative result; positive controls gave expected responses.

**Conclusion** Not mutagenic.

**Rev. note** Secondary literature.

**Klimisch criterium** 2 Secondary literature, non-GLP study.

**Repeated Dose:****9.4.40**

**Title** Final report on the safety assessment of sodium dodecylbenzenesulfonate/TEA-dodecylbenzenesulfonate/sodiumdecylbenzenesulfonate

**Date of report** 1997.

**GLP** No data

**Reference** 1

**Test substance** B, Benzenesulfonic acid, dodecyl-, compd. With 2,2',2''-nitrilotris(ethanol) (1:1), 0.5% a.i. in semipermanent hair dye.

**Guideline** Not indicated.

**Stat. method** Not applicable.

**Test system** **Species** Rabbit (New Zealand White).  
**No. of animals** 6/sex/dose group (3 control groups).  
**Dosage** 13 week-study with twice weekly dermal application of 1 ml/kg to the shaved skin (abraded in 3/sex/dose) with rinsing 1 hour after dosing.  
**Observations** Body weight weekly.  
Clinical chemistry, haematology and urinalysis at initiation and after 3, 7 and 13 weeks.  
Necropsy in week 13 (macro- and microscopy).

**Results** No treatment related effects. The significantly increased levels of BUN (all) and leukocyte count (males only) and decreased methaemoglobin level (females only) in treated animals were considered to be toxicologically irrelevant.

**Conclusions** NOAEL > 0.005 ml/kg bw (equivalent to 5 mg/kg bw); only dose tested

**Klimisch criterium** 2 A CTFA Cosmetic Ingredient Review

**9.4.42**

**Title** Toxicology Studies of Linear Alkylbenzene Sulphonate (LAS) in Rhesus Monkeys  
I. Simultaneous Oral and Subcutaneous Administration for 28 Days

**Date of report** 1978.

**GLP** No.

**Reference** 5

**Test substance** 2 (Benzenesulphonic acid, linear alkyl), purity 20.5% (78.7% water).

**Guideline** Not indicated.

**Stat. method** Not indicated.

**Test system** **Species** Rhesus Monkey (*Macaca mulatta*), 2.0-4.4 kg, age 18-36 months.  
**No. of animals** 3/sex/treatment.  
**Dosage** Simultaneous oral (gavage) and subcutaneous administration of 30 p.o./0.1 s.c., 150 p.o./0.5 s.c. and 300 p.o./1.0 s.c. mg/kg during 28 days; dose volume 4 ml/kg (p.o.) and 0.17 ml/kg (s.c.); vehicle (water) controls.  
**Observations** As per OECD 407 with the exception of some clinical chemical parameters (cholesterol, albumine and creatinine).

## Results

| Dose (mg/kg bw)                         | 0/0 | 30/0.1                       | 150/0.5 | 300/1.0 | DR |
|---|-----|------------------------------|---------|---------|----|
| Mortality                               |     | None                         |         |         |    |
| Clinical signs- systemic <sup>(A)</sup> |     |                              | +       | +       | x  |
| - local <sup>(B)</sup>                  |     | +                            | +       | +       | x  |
| Body weight gain/food consumption       |     | No treatment related effects |         |         |    |
| Ophthalmoscopy                          |     | No treatment related effects |         |         |    |
| Blood parameters/urine analysis         |     | No treatment related effects |         |         |    |
| Organ weights                           |     | No treatment related effects |         |         |    |
| Macroscopy/histopathology               |     | No treatment related effects |         |         |    |

(A) Vomiting (~3 h after application) and abnormal faeces.

(B) Chronic inflammatory cell infiltration (mainly fibroblasts) at the injection site associated with pseudocysts, haemorrhage and necrosis.

**Conclusions** NOAEL = 301 mg/kg  $\Leftrightarrow$  60 mg a.i./kg.

**Rev. note** 1. Clinical signs were treatment related but not considered to be significantly adverse.  
2. Most probably no statistical evaluation of the results was performed in view of the low number of animals in this study.

**Klimisch criterium** 2 Non-GLP study

## 9.4.47

**Title** Ultrastructural observations of the protective effect of glycyrrhizin for mouse liver injury caused by oral administration of detergent ingredient (LAS)

**Date of report** 1977.

**GLP** No.

**Reference** 30

**Test substance** 2 (Benzenesulphonic acid, linear alkyl).

**Guideline** Not indicated.

**Stat. method** Not indicated.

**Test system** **Species** Mouse (DDY-strain).

**No. of animals** Not indicated.

**Dosage** Administration for 6 months at 0 and 100 ppm in drinking water with 2 months recovery  $\Leftrightarrow$  males: 0 and 17 mg/kg bw, females: 0 and 20 mg/kg bw.

**Observations** Microscopical examination (electron microscope) of liver tissues of animals sacrificed at 1, 2, 3, 6 and 8 months after study initiation.

**Results** Hypofunctional and injured liver cells with disappeared nucleolonema, atrophic Golgi apparatus, degranulation of RER and mitochondria and increased number of lysosomes with autophagic vacuoles. After the recovery period mitochondria were still altered and in some hepatic cells fatty metamorphosis was observed.

**Conclusions** Liver effects at 17 mg/kg bw.

**Rev. note** 1. No information on accuracy of preparation, stability and homogeneity was provided. The actual test substance intake was calculated by the reviewer from estimated water intake of 5 ml/day and a mean bodyweight 30 g for males and 25 g for females.

2. The information in this journal article was limited to the above-mentioned.

3. The identity of the test substance could not be established (most probably #2).

**Klimisch criterium** 4 Limited report and no confirmation of test substance.

## Reproductive Toxicity:

### 9.4.48

|                           |   |   |
|---------------------------|---|---|
| <b>Title</b>              | Final report on the safety assessment of sodium dodecylbenzenesulfonate/TEA-dodecylbenzenesulfonate/sodiumdecylbenzenesulfonate |   |
| <b>Date of report</b>     | 1997.   |   |
| <b>GLP</b>                | No data   |   |
| <b>Reference</b>          | 1   |   |
| <b>Test substance</b>     | B, Benzenesulfonic acid, dodecyl-, compd. with 2,2',2''-nitrilotris(ethanol) (1:1), 0.2-0.3% a.i. in semipermanent hair dye.    |   |
| <b>Guideline</b>          | Not indicated.  |   |
| <b>Stat. method</b>       | Not applicable.   |   |
| <b>Test system</b>        | <b>Species</b>  | Rat (CD).   |
|                           | <b>No. of animals</b>   | 25 males/dose group in the P-group.   |
|                           | <b>Dosage</b>   | Twice weekly dermal application of 0.5 ml/kg to the shaved skin during 10 weeks.  |
|                           | <b>Procedure</b>  | After 10 weeks of dosing, males were mated with untreated females to produce 75 mated females/group. Females were allowed to deliver and 2 healthy 21-day-old F1-males were selected from each litter to mate after 12 weeks with untreated females to produce 300 mated females. These females were killed on day 4-16 of gestation. |
|                           | <b>Observations</b>   | Number and sex of pups of the F1-generation (live and dead pups)<br>Uteri and offspring of the females mated to F1-males.   |
| <b>Results</b>            | No treatment related effects.   |   |
| <b>Conclusions</b>        | NOAEL > 0.0015 ml/kg bw (equivalent to 1.5 mg/kg bw); only dose tested  |   |
| <b>Klimisch criterium</b> | 2 A CTFA Cosmetic Ingredient Review   |   |

### 9.4.50

|                           |   |   |
|---------------------------|---|---|
| <b>Title</b>              | Effect of alcohol sulfate, linear alkylbenzene sulfonate and natural soap on the development of fertilized eggs of the mouse in vitro |   |
| <b>Date of report</b>     | 1990.   |   |
| <b>GLP</b>                | No.   |   |
| <b>Reference</b>          | 7   |   |
| <b>Test substance</b>     | 2 (Benzenesulphonic acid, linear alkyl), purity not indicated.  |   |
| <b>Guideline</b>          | Not applicable.   |   |
| <b>Stat. method</b>       | Not indicated.  |   |
| <b>Test system</b>        | <b>Cells</b>  | Fertilised mouse embryo cells.  |
|                           | <b>Test concentration</b>   | 0.015, 0.025, 0.03 and 0.05% during 1 h.<br>0.01, 0.025 and 0.05% for 5 days.   |
|                           | <b>Procedure</b>  | <i>In vitro</i> fertilised eggs at the pronucleus stage were incubated in culture medium containing the test substance for 1 h and observed for 5 days, or incubated for all 5 days of development. |
|                           | <b>Observations</b>   | Embryo development and blastocyst formation frequency   |
| <b>Results</b>            | 1 hr test: no impairment of development at 0.015% or 0.025%; at ≥0.03% there was no development (1-cell stage).                       |   |
|                           | 5 day test: at ≥0.025% there was no development (1-cell stage).   |   |
| <b>Conclusion</b>         | NOAEL 0.025% (1 hr) and 0.01% (5 day).  |   |
| <b>Klimisch criterium</b> | 2 Secondary literature.   |   |

#### 9.4.52

|                       |   |
|-----------------------|---|
| <b>Title</b>          | LAS-Mg : Effects upon the reproductive performance of rats treated continuously through two successive generations  |
| <b>Date of report</b> | April 19, 1982.   |
| <b>GLP</b>            | No (QA statement included).   |
| <b>Reference</b>      | 29  |
| <b>Test substance</b> | 3, Magnesium salt of LAS, purity 38% (slurry).  |
| <b>Guideline</b>      | Not indicated.  |
| <b>Stat. method</b>   | Multiple t-test, Mann-Whitney U-test, chi-square test, Fisher's test.   |
| <b>Test system</b>    | <b>Species</b> Rat (CD), 30-40 days old, weight 66-90 g (males) and 64-85 g (females).<br><b>No. of animals</b> P0/F1/F2 12M + 24F/dose level.<br><b>Dosage</b> Continuous dietary administration at 0, 1250, 2500 and 5000 ppm (nominal a.i.) $\leftrightarrow$ 0, 50, 103 and 222 mg a.i./kg bw (mean measured) during the entire study period.<br><b>Procedures</b> Males and females were mated (1:2) starting on day 91 (maximum 21 days) to produce the F1 <sub>A</sub> . After ~ 55 days females were re-mated with fresh males to produce the F1 <sub>B</sub> . The detection of a vaginal plug and/or presence of spermatozoa in a vaginal smear was used to define day 1 of gestation.<br>Selected F1 <sub>B</sub> animals were mated after a maturation period of 91 days according to the same scheme used for the P0 to produce the F2 <sub>A</sub> and F2 <sub>B</sub> generation.<br>Selected F2 <sub>B</sub> animals were killed after a maturation period of 91 days.<br><b>Analyses</b> In week 0, 26 and 52.<br><b>Observations</b> Parents <ul style="list-style-type: none"><li>• Mortality/clinical signs P0/F1/F2.</li><li>• Body weight males weekly, females weekly and on day 1,3,7,14 and 21 of gestation and on day 1,7, 14 and 21 after parturation (day 25 (after the second litter only)).</li><li>• Food and water intake weekly.</li><li>• Gestation duration/Oestrus cycle.</li><li>• Macroscopy P0/F1/F2.</li><li>• Macroscopy (related to neoplasms)/organ weights F2</li><li>• histopathology on 5/sex of F2 only (+ on animals with macroscopic findings).</li></ul> Offspring <ul style="list-style-type: none"><li>• Clinical signs.</li><li>• Mortality (visceral examination of dead pups).</li><li>• Litter size daily until day 21 or 25 (second litters).</li><li>• Body weight (individually on day 1 and total litter weight on day 4, 10, 14 and 21 (day 25 for second litters)).</li><li>• Startle response and pupil closure on day 21 or 25</li><li>• Macroscopy on pups not selected for the production of the next generation.</li></ul> |

| Results  | Analyses                     |   | Measured concentration 73-103% of nominal. |   |      |   |      |   |    |   |                 |
|--|------------------------------|---|--|---|------|---|------|---|----|---|-----------------|
| Dose (ppm a.i. in diet)                            | 0                            |   | 1250                                       |   | 2500 |   | 5000 |   | DR |   |                 |
| Dose (mean measured mg a.i./kg bw <sup>(A)</sup> ) | 0                            |   | 50   |   | 103  |   | 222  |   |    |   |                 |
|  | M                            | F | M  | F | M    | F | M    | F | M  | F |                 |
| P0   |                              |   |  |   |      |   |      |   |    |   |                 |
| Mortality  | 1/24 1/12                    |   |  |   |      |   |      |   |    |   |                 |
| Clinical signs                                     | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Body weight - wk 13                                |                              |   |  |   |      |   |      |   |    |   | dc              |
| - wk 28  |                              |   |  |   |      |   |      |   |    |   | d               |
| - weaning  |                              |   |  |   |      |   |      |   |    |   | d               |
| Food consumption                                   | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Water consumption                                  | d                            |   |  |   |      |   |      |   |    |   | d               |
| Mating success/fertility                           | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Gestation time/oestrus cycle                       | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Litter size  | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Live pups (until weaning)                          | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Pup body weight (gain)(F1 <sub>A</sub> )           | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| (F1 <sub>B</sub> )                                 |                              |   |  |   |      |   |      |   |    |   | dc              |
| Pup clinical signs/behaviour                       | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Pup macroscopy                                     | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Parent macroscopy                                  | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| F1 (selected animals)                              |                              |   |  |   |      |   |      |   |    |   |                 |
| Mortality  | 1/24 1/24                    |   |  |   |      |   |      |   |    |   |                 |
| Clinical signs                                     | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Body weight - wk 13                                |                              |   |  |   |      |   |      |   |    |   | dc              |
| - weaning  |                              |   |  |   |      |   |      |   |    |   | d               |
| Food/water consumption                             | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Mating success/fertility                           | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Gestation time/oestrus cycle                       | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Litter size (F2 <sub>A</sub> )                     | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| (F2 <sub>B</sub> ) day 0-25                        | d d                          |   |  |   |      |   |      |   |    |   |                 |
| Live pups (until weaning) (F2 <sub>A</sub> )       | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| (F2 <sub>B</sub> )                                 | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Pup body weight (gain)(F2 <sub>A</sub> )           | dc (10%)                     |   |  |   |      |   |      |   |    |   | dc (21%)        |
| (F2 <sub>B</sub> )                                 |                              |   |  |   |      |   |      |   |    |   | X               |
| Pup clinical signs/behaviour                       | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Pup macroscopy                                     | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Parent macroscopy                                  | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| F2 (selected animals)                              |                              |   |  |   |      |   |      |   |    |   |                 |
| Mortality  |                              |   |  |   |      |   |      |   |    |   | 1/24            |
| Clinical signs                                     | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Body weight  |                              |   |  |   |      |   |      |   |    |   | d               |
| Food consumption                                   |                              |   |  |   |      |   |      |   |    |   | d               |
| Water consumption                                  | d                            |   |  |   |      |   |      |   |    |   | d               |
| Macroscopy   | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |
| Organ weights                                      |                              |   |  |   |      |   |      |   |    |   |                 |
| Heart/spleen                                       |                              |   |  |   |      |   |      |   |    |   | dc <sup>a</sup> |
| Lungs/kidneys                                      |                              |   |  |   |      |   |      |   |    |   | dc <sup>a</sup> |
| Adrenals   |                              |   |  |   |      |   |      |   |    |   | ic <sup>r</sup> |
| Prostate   |                              |   |  |   |      |   |      |   |    |   |                 |
| Histopathology                                     | No treatment related effects |   |  |   |      |   |      |   |    |   |                 |

(A) Based on a mean food intake of 45 mg/kg bw (calculation by the reviewer)

**Conclusions** "Continuous administration of LAS-Mg to male and female rats, at dietary concentrations of 2500 and 5000 ppm, over two generations, was associated with slight retardation of somatic growth, but there were no adverse effects upon reproductive performance or fertility. The responses of animals receiving LAS-Mg at 1250 ppm were essentially similar to the controls."

NOAEL for reproductive effects is 222 mg/kg bw.

NOAEL based on growth of F2 pups up through lactation is 50 mg/kg bw.

|                           |   |
|---------------------------|---|
| <b>Rev. note</b>          | <ol style="list-style-type: none"> <li>1. The reduced litter size and reduced mean number of live pups in the F2B group treated at 1250 ppm could be attributed to the loss of a single litter.</li> <li>2. The effects on organ weights were related to the reduced body weights seen in the highest dose group. The increased weight of the adrenals in this group could be attributed to a single female (no macroscopic investigation of this animal was performed). The increased relative prostate weight could be attributed to a single male (macroscopic investigation did not confirm this).</li> </ol> |
| <b>Klimisch criterium</b> | 1   |

### ***Developmental Toxicity and Teratogenicity:***

#### **9.4.53**

|                           |   |  |
|---------------------------|---|--|
| <b>Title</b>              | Final report on the safety assessment of sodium dodecylbenzenesulfonate/TEA-dodecylbenzenesulfonate/sodiumdecylbenzenesulfonate |  |
| <b>Date of report</b>     | 1997.   |  |
| <b>GLP</b>                | No data   |  |
| <b>Reference</b>          | 1   |  |
| <b>Test substance</b>     | B, Benzenesulfonic acid, dodecyl-, compd. with 2,2',2''-nitritotris(ethanol) (1:1), 0.5% a.i. in semipermanent hair dye.        |  |
| <b>Guideline</b>          | Not indicated.  |  |
| <b>Stat. method</b>       | Not applicable.   |  |
| <b>Test system</b>        | <b>Species</b>  | Rat (CD).  |
|                           | <b>No. of animals</b>   | 20 females/dose group (3 control groups).  |
|                           | <b>Dosage</b>   | Dermal application of 2 ml/kg to the shaved skin on day 1, 4, 7, 10, 13, 16 and 19 of gestation. |
|                           | <b>Observations</b>   | Necropsy on day 20 and examination of foeteuses  |
| <b>Results</b>            | No treatment related effects.   |  |
| <b>Conclusions</b>        | NOAEL > 0.01 ml/kg bw (equivalent to 10 mg/kg bw); only dose tested   |  |
| <b>Klimisch criterium</b> | 2   | A CTFA Cosmetic Ingredient Review.   |

#### **9.4.54**

|                       |   |  |
|-----------------------|---|--|
| <b>Title</b>          | A Teratology Study of Topically Applied Linear Alkylbenzene Sulphonate in Rats  |  |
| <b>Date of report</b> | 1980.   |  |
| <b>GLP</b>            | No data   |  |
| <b>Reference</b>      | 2   |  |
| <b>Test substance</b> | 2 (Benzenesulphonic acid, linear alkyl), purity 20.5% (0.2% alkylbenzene, 0.6% ash, 78.7% water).                     |  |
| <b>Guideline</b>      | Not indicated.  |  |
| <b>Stat. method</b>   | F-test, Student's <i>t</i> -test (when applicable chi-square). Test groups were compared with water treated controls. |  |
| <b>Test system</b>    | <b>Species</b>  | Rat (Wistar), age 12-18 weeks.   |
|                       | <b>No. of animals</b>   | 20-21 mated females/treatment.   |
|                       | <b>Dosage</b>   | Dermal application of 1, 2, 10, 20, 100 and 400 mg/kg bw (0.5 ml in tap water) on the clipped skin (24 cm <sup>2</sup> , 10% of body surface); unclipped, clipped but not treated and clipped water treated controls; at 20, 100 and 400 mg/kg the test substance was washed off with water after 30 min.  |
|                       | <b>Procedures</b>   | Female rats were mated with untreated males (1/1) from the same strain. The day of observation of sperm was defined as day 0 of gestation. Females were treated daily from day 0 to 20 of gestation inclusive. Body weight, food consumption and clinical signs were recorded daily. All females were subjected to macroscopic examination on day 21. The uteri were removed and examined for no. of corpora lutea, no. of implantation sites and no. and location of foetuses and resorptions. Foetuses were inspected on total number, viability, sex, |

weight and external, visceral and neural (½ of foetuses) and skeletal (½ of foetuses) defects. The number of vertebrae and phalanges was recorded.

## Results

| Dose (mg/kg bw)                                  | 0<br>(unclip ped)            | 0<br>(clip ped) | 0<br>(veh. d) | 1     | 2     | 10    | 20    | 100   | 400   | DR |
|--|------------------------------|-----------------|---------------|-------|-------|-------|-------|-------|-------|----|
| <i>Maternal data</i>                             |                              |                 |               |       |       |       |       |       |       |    |
| Mortality  | None                         |                 |               |       |       |       |       |       |       |    |
| Clinical signs <sup>(A)</sup>                    |                              |                 |               |       |       |       |       |       |       | x  |
| Mean body weight day 12-21                       |                              |                 |               |       |       |       |       |       |       |    |
| Food intake                                      | No treatment related effects |                 |               |       |       |       |       |       |       |    |
| Necropsy   | Not reported                 |                 |               |       |       |       |       |       |       |    |
| No. of pregnant females                          | 20/20                        | 20/20           | 20/20         | 19/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/21 |    |
| No. of corpora lutea and implantation sites /dam | No treatment related effects |                 |               |       |       |       |       |       |       |    |
| Implantation loss/ resorptions                   | No treatment related effects |                 |               |       |       |       |       |       |       |    |
| No. live foetuses/ dam                           | No treatment related effects |                 |               |       |       |       |       |       |       |    |
| <i>Foetal data</i>                               |                              |                 |               |       |       |       |       |       |       |    |
| No. of litters included in evaluations           | 19                           | 20              | 20            | 19    | 20    | 20    | 20    | 20    | 20    |    |
| Foetal weight / sex                              | No treatment related effects |                 |               |       |       |       |       |       |       |    |
| External, visceral/neural/ Skeletal examination  | No treatment related effects |                 |               |       |       |       |       |       |       |    |
| No. vertebrae and phalanges                      | No treatment related effects |                 |               |       |       |       |       |       |       |    |

(A)Discolouration ((light) brown), erythema, fissuring and slight thickening of the skin. Reported as "marked" at 400, "slight" at 100, and discolouration only at 20.

|                           |  |
|---------------------------|--|
| <b>Conclusions</b>        | <p>"This study demonstrated that LAS is free of teratogenic and embryopathic effects when applied to the dermis of pregnant Wistar rats at concentrations that elicit marked skin changes and reductions in maternal body weight.</p> <p>NOAEL for maternal toxicity: 100 mg/kg bw ⇔ 20.1 mg a.i./kg bw (based on 5% weight loss).</p> <p>NOAEL for reproductive effects: 400 mg/kg bw ⇔ 82 mg a.i./kg bw.</p> |
| <b>Rev. note</b>          | <p>1. The test substance was only applied for 30 minutes daily for 20, 100 and 400 mg/kg bw dose groups).</p> <p>2. Clinical signs were treatment related but not considered toxicologically significant.</p>  |
| <b>Klimisch criterium</b> | 2 Non-GLP study  |

## 9.4.55

|                       |  |
|-----------------------|--|
| <b>Title</b>          | Assessment of the teratogenic potential of surfactants Part 1 – LAS, AS and CLD  |
| <b>Date of report</b> | 1975.  |
| <b>GLP</b>            | No.  |
| <b>Reference</b>      | 18   |
| <b>Test substance</b> | 2 (Benzenesulphonic acid, linear alkyl), purity not indicated.   |
| <b>Guideline</b>      | Not indicated.   |
| <b>Stat. method</b>   | Wilcoxon-test.   |
| <b>Test system</b>    | <p><b>Species</b> Rabbit (New Zealand White), rat (CD) and mouse (CD-1).</p> <p><b>No. of animals</b> 20 females/treatment (13 for rabbits).</p> <p><b>Dosage</b> Administration by oral gavage at 0.2, 2.0, 300 and 600 mg/kg bw (vehicle: water); vehicle treated controls; solutions were prepared daily.</p> <p><b>Procedures</b> Females were mated. The day of observation of a vaginal plug (rats and mice) or observation of coitus (rabbit) was defined as day 0 of gestation. Females were treated daily from day 6 to 15 (18 for rabbits) of gestation. Mortality/clinical symptoms of dams were noted daily. Body weight was recorded regularly. All females were subjected to</p> |



macroscopic examination day 17, 20 and 29 for mice, rats and rabbits, respectively, or on day of death. The uteri were removed and examined for no. of corpora lutea, no. of implantation sites and no. of fetuses and resorptions. Fetuses were inspected on total number, sex, weight and external, visceral (1/3 of fetuses in rats and mice, all in rabbits) and skeletal (2/3 of fetuses in rats and mice, all in rabbits) defects.

#### Results Mice

| Dose (mg/kg bw)                                     | 0     | 0.2                          | 2.0                          | 300   | 600   | DR |
|---|-------|------------------------------|------------------------------|-------|-------|----|
| <i>Maternal data</i>                                |       |                              |                              |       |       |    |
| <b>Mortality</b>                                    | 0/20  | 0/20                         | 0/20                         | 7/20  | 18/20 | x  |
| <b>Clinical signs</b> <sup>(A)</sup>                |       |                              |                              | +     | +     |    |
| <b>Body weight gain</b>                             |       |                              |                              | d     | d     | x  |
| <b>Necropsy</b>                                     |       |                              | Not reported                 |       |       |    |
| <b>No. of pregnant females</b>                      | 17/20 | 18/20                        | 18/20                        | 20/20 | 19/20 |    |
| <b>No. of implantation sites /dam</b>               |       |                              | No treatment related effects |       |       |    |
| <b>Pre-implantation loss</b>                        |       |                              | Not reported                 |       |       |    |
| <b>Post-implantation loss/ resorptions</b>          |       |                              |                              |       | i     |    |
| <b>No. live fetuses/ dam</b>                        |       |                              |                              | dc    | N/A   | x  |
| <i>Foetal data</i>                                  |       |                              |                              |       |       |    |
| <b>No. of litters included in evaluations</b>       | 17    | 18                           | 18                           | 9     | N/A   |    |
| <b>Foetal weight</b>                                |       | ic                           |                              |       | N/A   |    |
| <b>External examination / sex</b>                   |       | No treatment related effects |                              |       | N/A   |    |
| <b>Anomalies: visceral/ skeletal</b> <sup>(B)</sup> |       |                              |                              | i     | N/A   |    |

(A) Disturbance of the gastro-intestinal tract.

(B) No details provided.

#### Results Rats

| Dose (mg/kg bw)  | 0     | 0.2                          | 2.0                          | 300   | 600   | DR |
|--|-------|------------------------------|------------------------------|-------|-------|----|
| <i>Maternal data</i>                                     |       |                              |                              |       |       |    |
| <b>Mortality</b>   | 0/20  | 0/20                         | 0/20                         | 0/20  | 1/20  |    |
| <b>Clinical signs</b> <sup>(A)</sup>                     |       |                              |                              |       | +     |    |
| <b>Body weight gain</b>                                  |       |                              |                              |       | d     |    |
| <b>Necropsy</b>  |       |                              | Not reported                 |       |       |    |
| <b>No. of pregnant females</b>                           | 15/20 | 15/20                        | 18/20                        | 16/20 | 17/20 |    |
| <b>No. of corpora lutea / implantation sites per dam</b> |       |                              | No treatment related effects |       |       |    |
| <b>Pre/post-implantation loss/ resorptions</b>           |       |                              | No treatment related effects |       |       |    |
| <b>No. live fetuses/ dam</b>                             |       |                              | No treatment related effects |       |       |    |
| <i>Foetal data</i>                                       |       |                              |                              |       |       |    |
| <b>No. of litters included in evaluations</b>            | 15    | 14                           | 18                           | 16    | 16    |    |
| <b>Foetal weight</b>                                     |       | ic                           | ic                           |       |       |    |
| <b>External examination / sex</b>                        |       | No treatment related effects |                              |       |       |    |
| <b>Anomalies: visceral/ skeletal</b>                     |       | No treatment related effects |                              |       |       |    |

(A) Disturbance of the gastro-intestinal tract.

#### Results Rabbits

| Dose (mg/kg bw)  | 0     | 0.2   | 2.0                          | 300   | 600   | DR |
|--|-------|-------|------------------------------|-------|-------|----|
| <i>Maternal data</i>                                     |       |       |                              |       |       |    |
| <b>Mortality</b>   | 2/13  | 0/13  | 1/13                         | 11/13 | 13/13 | x  |
| <b>Clinical signs</b> <sup>(A)</sup>                     |       |       |                              | +     | +     |    |
| <b>Body weight gain</b>                                  |       |       |                              | d     | d     | x  |
| <b>Necropsy</b>  |       |       | Not reported                 |       |       |    |
| <b>No. of pregnant females</b>                           | 12/13 | 13/13 | 12/13                        | 2/13  | 0/13  |    |
| <b>No. of corpora lutea / implantation sites per dam</b> |       |       | No treatment related effects |       | N/A   |    |
| <b>Pre-implantation loss</b>                             |       |       | No treatment related effects |       |       |    |
| <b>Post-implantation loss/ resorptions</b>               |       |       |                              | i     | N/A   |    |
| <b>No. live fetuses/ dam</b>                             |       |       |                              | dc    | N/A   | x  |
| <i>Foetal data</i>                                       |       |       |                              |       |       |    |

|   |                              |    |    |     |     |
|---|------------------------------|----|----|-----|-----|
| <b>No. of litters included in evaluations</b>       | 9                            | 12 | 11 | 2   | N/A |
| <b>Foetal weight</b>                                | No treatment related effects |    |    | N/A | N/A |
| <b>External examination / sex</b>                   | No treatment related effects |    |    | N/A | N/A |
| <b>Anomalies: visceral/ skeletal <sup>(B)</sup></b> | No treatment related effects |    |    | N/A | N/A |

(A)Diarrhoea, anorexia and cachexia were seen among animals.

|                           |  |
|---------------------------|--|
| <b>Conclusions</b>        | <p>"Effects on litter parameters were generally restricted to dosages causing marked maternal toxicity, the principal effects being higher foetal loss (with consequent reduction in litter size) arising from the increased incidence of total litter loss. When dams showing total litter loss were excluded from the calculations, litter parameters were not unduly different from those of controls. At dosages that were either non-toxic or only slightly to moderately toxic to the dam, litter parameters were essentially unaffected."</p> <p>NOAEL for maternal toxicity: &gt; 2 but &lt;300 mg/kg for mice and rabbits; 300 mg/kg for rats.</p> <p>There were no teratogenic and embryotoxic effects observed at any dose level.</p> |
| <b>Rev. note</b>          | <ol style="list-style-type: none"> <li>Limited information was available on the identity of the test substance. It was assumed by the reviewer that the test substance was the benzenesulphonic acid, linear alkyl.</li> <li>Effects on reproduction were seen at doses exhibiting maternal toxicity.</li> <li>Anomalies reported in foetuses and sex of the foetuses were not identified.</li> <li>Large (&gt;100 X) gap in doses between NOAEL and LOAEL for maternal toxicity for mice and rabbits makes it difficult to establish a true NOAEL.</li> </ol>   |
| <b>Klimisch criterium</b> | <ol style="list-style-type: none"> <li>Question regarding identity of test substance. Non-GLP study.</li> </ol>  |

#### 9.4.56

|                       |  |   |
|-----------------------|--|---|
| <b>Title</b>          | Assessment of the teratogenic potential of surfactants Part III – Dermal application of LAS and Soap |   |
| <b>Date of report</b> | 1975.  |   |
| <b>GLP</b>            | No.  |   |
| <b>Reference</b>      | 19   |   |
| <b>Test substance</b> | 2 (Benzenesulphonic acid, linear alkyl), purity not indicated.                                       |   |
| <b>Guideline</b>      | Not indicated.   |   |
| <b>Stat. method</b>   | Wilcoxon-test.   |   |
| <b>Test system</b>    | <b>Species</b>   | Rabbit (New Zealand White), rat (CD) and mouse (CD-1).  |
|                       | <b>No. of animals</b>  | 20 females/treatment (13 for rabbits).  |
|                       | <b>Dosage</b>  | Dermal application of 0.03, 0.30 and 3.00% solutions (vehicle: water) to 240, 16 and 6 cm <sup>2</sup> for rabbits, rats and mice resp.(dosing volume 0.5 (rat, mouse) or 10 ml (rabbit)); vehicle treated controls; solutions were prepared daily; application in two parts (with drying period, no occlusion).  |
|                       | <b>Procedures</b>  | Females were mated. The day of observation of a vaginal plug (rats and mice) or observation of coitus (rabbit) was defined as day 0 of gestation. Females were treated daily from day 2 to 15 (rats), 2 to 13 (mice) and 1-16 (rabbits) of gestation. Mortality/clinical symptoms of dams were noted daily. Body weight was recorded regularly. All females were subjected to macroscopic examination day 17, 20 and 29 for mice, rats and rabbits resp. or on day of death. The uteri were removed and examined for no. of corpora lutea, no. of implantation sites and no. of foetuses and resorptions. Foetuses were inspected on total number, sex, weight and external, visceral (1/3 of foetuses in rats and mice,all in rabbits) and skeletal (2/3 of foetuses in rats and mice,all in rabbits) defects. |

## Results Mice

| Dose (%)                                     | 0     | 0.03                         | 0.3   | 3        | DR |
|--|-------|------------------------------|-------|----------|----|
| Dose (mg/kg bw)                              | 0     | 5                            | 50    | 500      |    |
| Maternal data                                |       |                              |       |          |    |
| Mortality                                    | 1/20  | 1/20                         | 0/20  | 0/20     | x  |
| Clinical signs <sup>(A)</sup>                |       |                              | +     | +        |    |
| Body weight gain                             |       |                              |       | d        |    |
| Necropsy                                     |       | Not reported                 |       |          | x  |
| No. of pregnant females                      | 17/20 | 16/20                        | 18/20 | 6/20     |    |
| No. of implantation sites /dam               |       | No treatment related effects |       |          |    |
| Post-implantation loss/ resorptions          |       |                              | l     | i        |    |
| No. live foetuses/ dam                       |       |                              |       | d        |    |
| Foetal data                                  |       |                              |       |          |    |
| No. of litters included in evaluations       | 14    | 15                           | 14    | 1        |    |
| Foetal weight                                |       | No treatment related effects |       |          |    |
| External examination                         |       | No treatment related effects |       |          |    |
| Anomalies: visceral/ skeletal <sup>(B)</sup> |       |                              |       | N/A<br>i |    |

(A) Erythema, oedema (peak on day 6, dead skin), irritability and hypersensitivity were seen among animals. Effects were reversible

(B) No visceral examination of fetuses of high dosed females. Skeletal examinations revealed extra ribs (cervical).

## Results Rats

| Dose (%)  | 0                            | 0.03  | 0.3   | 3     | DR |
|---|------------------------------|-------|-------|-------|----|
| Dose (mg/kg bw)                                   | 0                            | 0.6   | 6     | 60    |    |
| Maternal data                                     |                              |       |       |       |    |
| Mortality   | None                         |       |       |       |    |
| Clinical signs <sup>(A)</sup>                     | +                            |       |       |       |    |
| Body weight gain                                  | No treatment related effects |       |       |       |    |
| Necropsy  | Not reported                 |       |       |       |    |
| No. of pregnant females                           | 20/20                        | 18/20 | 20/20 | 18/20 |    |
| No. of corpora lutea / implantation sites per dam | No treatment related effects |       |       |       |    |
| Pre/post-implantation loss/ resorptions           | No treatment related effects |       |       |       |    |
| No. live fetuses/ dam                             | No treatment related effects |       |       |       |    |
| Foetal data                                       |                              |       |       |       |    |
| No. of litters included in evaluations            | 19                           | 18    | 20    | 18    |    |
| Foetal weight                                     |                              |       |       | ic    |    |
| External examination                              | No treatment related effects |       |       |       |    |
| Anomalies: visceral/ skeletal                     | No treatment related effects |       |       |       |    |

(A) Erythema, oedema (peak on day 4-5), irritability and hypersensitivity were seen among animals. Effects were reversible.

## Results Rabbits

| Dose (%)  | 0                            | 0.03         | 0.3   | 3     | DR |
|---|------------------------------|--------------|-------|-------|----|
| Dose (mg/kg bw)                                   | 0                            | 0.9          | 9     | 90    |    |
| Maternal data                                     |                              |              |       |       |    |
| Mortality   | 0/13                         | 0/13         | 1/13  | 0/13  |    |
| Clinical signs <sup>(A)</sup>                     |                              |              | +     | +     |    |
| Body weight gain                                  |                              |              | D     | d     |    |
| Necropsy  |                              | Not reported |       |       |    |
| No. of pregnant females                           | 12/13                        | 12/13        | 13/13 | 11/13 |    |
| No. of corpora lutea / implantation sites per dam | No treatment related effects |              |       |       |    |
| Pre/post-implantation loss/ resorptions           |                              |              |       | i     |    |
| No. live fetuses/ dam                             |                              |              |       | d     |    |
| Foetal data                                       |                              |              |       |       |    |
| No. of litters included in evaluations            | 11                           | 12           | 12    | 9     |    |
| Foetal weight                                     | No treatment related effects |              |       |       |    |
| External examination                              | No treatment related effects |              |       |       |    |
| Anomalies: visceral/ skeletal                     | No treatment related effects |              |       |       |    |

(A) Erythema, oedema (peak on day 6-7, cracking and bleeding skin), irritability and hypersensitivity were seen among animals.

|                           |   |
|---------------------------|---|
| <b>Conclusions</b>        | <p>"Effects on litter parameters were generally restricted to dosages causing marked maternal toxicity in mice, the principal effects being higher foetal loss (with consequent reduction in viable litter size) arising from an increased incidence of total litter losses. When dams showing total litter loss were excluded from the calculations, litter parameters were not unduly different from those of controls. Although LAS at 3% was considered to show marked maternal toxicity in the rabbit, the slightly higher foetal loss and lower litter size did not differ significantly from control values. The moderate maternal toxicity of LAS, 0.3% in the mouse correlated with a higher incidence of embryonic deaths and lower litter size but only the former differed significantly from the corresponding control value. At dosages that were non-toxic or only slightly toxic to the dam, litter parameters were not adversely affected... The incidence of major malformations, minor visceral or skeletal anomalies, and skeletal variants provided no conclusive evidence of specific teratogenicity even at maternally toxic dosages."</p> <p>NOAEL for maternal toxicity: 0.3% = 50 mg/kg bw (mice), 0.3% = 9 mg/kg bw (rabbits) and 3% = 60 mg/kg bw (rats)</p> <p>NOAEL for teratogenic and embryotoxic effects: no effects at any dose level</p> |
| <b>Rev. note</b>          | <ol style="list-style-type: none"> <li>Effects on reproduction were seen at doses exhibiting maternal toxicity</li> <li>Limited information was available on the identity of the test substance. It was assumed by the reviewer that the test substance was the benzenesulphonic acid, linear alkyl.</li> <li>Clinical signs were treatment related but not considered toxicologically significant.</li> </ol>  |
| <b>Klimisch criterium</b> | <ol style="list-style-type: none"> <li>Question regarding identify of test substance. Non-GLP study.</li> </ol>   |

#### 9.4.57

|                       |   |
|-----------------------|---|
| <b>Title</b>          | LAS-Mg : Effects of oral administration upon the progress and outcome of pregnancy in the rabbit  |
| <b>Date of report</b> | December 21, 1978.  |
| <b>GLP</b>            | No.   |
| <b>Reference</b>      | 26  |
| <b>Test substance</b> | 3, Magnesium salt of LAS, purity not indicated.   |
| <b>Guideline</b>      | Not indicated.  |
| <b>Stat. method</b>   | Not indicated.  |
| <b>Test system</b>    | <p><b>Species</b> Rabbit (New Zealand White), body weight 2730-5200 g.</p> <p><b>No. of animals</b> 14 females/treatment.</p> <p><b>Dosage</b> Oral administration of 0, 60, 125 and 250 mg/kg bw (vehicle water) during day 6 to 18 of gestation; dosage volume 5 mL.</p> <p><b>Procedures</b> Females were mated with fertile males and injected with luteinising hormone on day 0 of gestation. Mortality and clinical signs of dams were noted daily. Body weights were recorded on day 0, 6, 8, 10, 12, 14, 16, 18, 23 and 28 of gestation. Food/water consumption was recorded on day 0, 5, 11, 17, 22 and 28. All females were killed on day 29 of gestation and subjected to macroscopic examination. The reproductive tract (incl. Ovaries) was dissected and examined for number of corpora lutea, implantations, early and late resorptions and foetuses. Foetuses were weighed, sexed and examined for external and skeletal abnormalities. Placenta weights were determined.</p> |

## Results

| Dose (mg/kg bw)                   | 0    | 60                           | 125  | 250  | DR |
|-----------------------------------|------|------------------------------|------|------|----|
| <b>Maternal</b>                   |      |                              |      |      |    |
| Mortality                         | 1/14 | 1/14                         | 2/14 | 0/14 |    |
| Clinical signs                    |      | Not reported                 |      |      |    |
| Body weight gain                  |      | d                            | d    | d    | X  |
| Food/water consumption (day 6-17) |      | d                            | d    | d    | X  |
| Macroscopy                        |      | No treatment related effects |      |      |    |
| Number of pregnancies             | 10   | 14                           | 12   | 13   |    |
| Corpora lutea/implantation sites  |      | No treatment related effects |      |      |    |
| Post implantation loss            |      |                              | i    | i    | X  |
| Resorptions early                 |      | No treatment related effects |      |      |    |
| Late                              |      |                              |      | i    | X  |
| Placental weight                  |      |                              |      | i    | X  |
| <b>Foetal</b>                     |      |                              |      |      |    |
| Number of litters evaluated       | 10   | 13                           | 12   | 11   |    |
| Number of live foetuses           |      |                              | d    | d    | X  |
| Weight/sex                        |      | No treatment related effects |      |      |    |
| External/Skeletal abnormalities   |      | No treatment related effects |      |      |    |

**Conclusions** "It was concluded from this investigation that LAS-Mg, administered to pregnant rabbits at dosages up to 250 mg/kg/day, had no adverse effects upon foetal morphology, although at dosages of 125 or 250 mg/kg/day survival *in-utero* was impaired. At dosages of 60 mg/kg day or above, there was some impairment of maternal economy, but no effects upon the foetus."

NOAEL for maternal effects = 60 mg/kg bw based on post implantation loss.

Effects on reproduction were observed at doses exhibiting maternal toxicity.

No teratogenicity or embryotoxicity were observed at any dose level.

**Rev. note** 1. The purity of the test substance is not indicated; therefore, a.i. dose could not be calculated.

2. No visceral examination of foetuses was performed.

**Klimisch criterium** 2 Non-GLP study; also Notes 1 and 2

## 9.4.58

|                       |   |
|-----------------------|---|
| <b>Title</b>          | LAS-Mg : Effects upon the progress and outcome of pregnancy in the rabbit   |
| <b>Date of report</b> | August 31, 1978.  |
| <b>GLP</b>            | No.   |
| <b>Reference</b>      | 27  |
| <b>Test substance</b> | 3, Magnesium salt of LAS, purity not indicated.   |
| <b>Guideline</b>      | Not indicated.  |
| <b>Stat. method</b>   | Not indicated.  |
| <b>Test system</b>    | <p><b>Species</b> Rabbit (New Zealand White), mean body weight 3800-4100 g.</p> <p><b>No. of animals</b> 14 females/treatment.</p> <p><b>Dosage</b> Topical application of 0, 0.75, 1.5 and 3.0% in PEG (3% aqueous) during day 6 to 18 of gestation; application volume 5 mL, application area 100 cm<sup>2</sup>.</p> <p><b>Procedures</b> Females were mated with fertile males and injected with luteinising hormone on day 0 of gestation. Body weights were recorded on day 0, 6, 8, 10, 12, 14, 16, 18, 23 and 28 of gestation. Food/water consumption was recorded on day 0, 5, 11, 17, 22 and 28. All females were killed on day 29 of gestation and subjected to macroscopic examination. The reproductive tract (incl. ovaries) was dissected and examined for number of corpora lutea, implantations, early and late resorptions and foetuses. Foetuses were weighed, sexed and examined for external and skeletal abnormalities. Placenta weights were determined.</p> |

## Results

| Results                          |    |                              |      |      |    |
|----------------------------------|----|------------------------------|------|------|----|
| Dose (%)                         | 0  | 0.75                         | 1.5  | 3.0  | DR |
| Maternal                         |    |                              |      |      |    |
| Mortality                        |    |                              | 1/14 | 1/14 |    |
| Clinical signs <sup>(A)</sup>    | +  | +                            | +    | +    | X  |
| Body weight (gain)               |    | No treatment related effects |      |      |    |
| Food/water consumption           |    | No treatment related effects |      |      |    |
| Macroscopy                       |    | No treatment related effects |      |      |    |
| Number of pregnancies            | 14 | 13                           | 12   | 11   |    |
| Corpora lutea/implantation sites |    | No treatment related effects |      |      |    |
| Resorptions                      |    | No treatment related effects |      |      |    |
| Placental weight                 |    | No treatment related effects |      |      |    |
| Foetal                           |    |                              |      |      |    |
| Number of litters evaluated      | 14 | 11                           | 11   | 11   |    |
| Number of live foetuses          |    | No treatment related effects |      |      |    |
| Weight/sex                       |    | No treatment related effects |      |      |    |
| External/Skeletal abnormalities  |    | No treatment related effects |      |      |    |

(A) Erythema and hyperkeratinisation.

|                           |   |
|---------------------------|---|
| <b>Conclusions</b>        | NOAEL for maternal effects 3%. Clinical signs were observed but not considered toxicologically significant.<br>NOAEL for reproductive effects 3%.   |
| <b>Rev. note</b>          | <ol style="list-style-type: none"> <li>The application area was less than 10% of the body surface.</li> <li>No information on the use of a (semi)occlusive dressing was available. If no dressing is used, some oral intake of the test substance can not be fully excluded.</li> <li>The purity of the test substance is not indicated. Therefore the actual amount (a.i.) applied can not be calculated.</li> <li>No visceral examination of foetuses was performed.</li> </ol> |
| <b>Klimisch criterium</b> | 2 Non-GLP study; also Notes 3 and 4.  |

### 9.4.59

|                       |  |   |  |
|-----------------------|--|---|--|
| <b>Title</b>          | LAS-Mg : The effects of topical application upon reproduction : Segment II study |   |  |
| <b>Date of report</b> | January 9, 1979.   |   |  |
| <b>GLP</b>            | No.  |   |  |
| <b>Reference</b>      | 28   |   |  |
| <b>Test substance</b> | 3, Magnesium salt of LAS, purity not indicated.                                  |   |  |
| <b>Guideline</b>      | Guidelines of Japanese Ministry of Health and Welfare.                           |   |  |
| <b>Stat. method</b>   | ANOVA.   |   |  |
| <b>Test system</b>    | <b>Species</b>   | Rat (CD), 12 weeks old, weight 242-298 g.   |  |
|                       | <b>No. of animals</b>  | 32 females/dose level.  |  |
|                       | <b>Dosage</b>  | Application of 0, 1.75, 3.5 and 7.0% test substance in 3%PEG to the clipped dorsal skin (area 32 cm <sup>2</sup> ) of F0 females; vehicle treated controls.   |  |
|                       | <b>Procedures</b>  | <p>F0:<br/>Female rats were mated with untreated males (1/1) from the same strain. The day of observation of sperm or a copulatory plug was defined as day 0 of gestation. Females were treated daily from day 7 to 17 of gestation inclusive.</p> <p>Two-thirds of the females were sacrificed on day 20 of gestation, the remaining females were allowed to deliver and their off-spring was observed for at least 8 weeks after parturition.</p> <p>F1:<br/>Selected off-spring from dams of the same treatment group was allowed to mate (22/sex/group, 1/1) at the age of ten weeks. The day of observation of sperm or a copulatory plug was defined as day 0 of gestation. On day 20 of gestation the females were sacrificed.</p> |  |
|                       | <b>Observations</b>  | <p><b>Maternal (F0)</b></p> <ul style="list-style-type: none"> <li>Mortality/clinical signs.</li> <li>Body weight on day 0, 2, 7, 9, 11, 13, 15, 17 and 20 of gestation.</li> </ul>   |  |

- Food and water intake twice weekly.

#### *Teratology (F0)*

- No. of corpora lutea.
- No. of implantation sites.
- No. and location of fetuses and resorptions.

#### *Foetuses (F1)*

- Total number.
- Sex, weight.
- External, visceral (½ of fetuses) and skeletal (½ of fetuses) defects.

#### *Post-natal (F0)*

- Body weight twice weekly until weaning.
- Gestation duration, parturition.
- Macroscopy.

#### *Young (F1)*

- No., sex, weight.
- Viability/abnormalities.
- Postnatal development (physical/behavioural).
- Macroscopy.

#### **Reproduction (F1)**

- No. of corpora lutea.
- No. of implantation sites.
- No. and location of fetuses and resorptions.
- Macroscopy (males and females).

#### *Foetuses (F2)*

- Total number.
- Sex, weight.
- External defects.

### **Results**

| Dose (%)   | 0    | 1.75                         | 3.5  | 7.0  | DR |
|--|------|------------------------------|------|------|----|
| F0 (prenatal)  |      |                              |      |      |    |
| Mortality  | None |                              |      |      | X  |
| Clinical signs <sup>(A)</sup>                            | +    |                              |      |      |    |
| Body weight (gestation)                                  | +    |                              |      |      |    |
| Food/water consumption <sup>(B)</sup>                    | +    |                              |      |      |    |
| Macroscopy <sup>(C)</sup>                                | d    |                              |      |      |    |
| Non-pregnant females                                     | 0/32 | No treatment related effects | 1/32 | 0/32 |    |
| Corpora lutea/implantation sites                         |      | No treatment related effects | 0/32 | 0/32 |    |
| Implantation loss/resorptions                            |      | No treatment related effects |      |      |    |
| Foetal evaluation (F1)                                   |      |                              |      |      |    |
| Number of litters evaluated                              | 11   | 11                           | 11   | 11   |    |
| Number of live foetuses                                  |      | No treatment related effects |      |      |    |
| Weight/sex   |      | No treatment related effects |      |      |    |
| External <sup>(D)</sup> /Skeletal/visceral abnormalities |      | No treatment related effects |      |      |    |
| F0 (postnatal)   |      |                              |      |      |    |
| Mortality/clinical signs                                 |      | No treatment related effects |      |      |    |
| Body weight (lactation)                                  |      | No treatment related effects |      |      |    |
| Gestation time/parturition                               |      | No treatment related effects |      |      |    |
| Evaluation of offspring (F1)                             |      |                              |      |      |    |
| Number of viable young                                   |      | No treatment related effects |      |      | d  |
| Body weight <sup>(E)</sup>                               |      |                              |      |      |    |
| Sex  |      | No treatment related effects |      |      |    |
| Postnatal development                                    |      | No treatment related effects |      |      |    |
| Macroscopy   |      | No treatment related effects |      |      |    |

|                                   | 0    | 1.75                         | 3.5    | 7.0  | DR |
|-----------------------------------|------|------------------------------|--------|------|----|
| <b>F1 (prenatal)</b>              |      |                              |        |      |    |
| Mortality                         |      |                              | 1 male |      |    |
| Clinical signs                    |      | No treatment related effects |        |      |    |
| Body weight                       |      | No treatment related effects |        |      |    |
| Mating success                    |      | No treatment related effects |        |      |    |
| Non-pregnant females              | 2/22 | 1/22                         | 0/22   | 0/22 |    |
| Corpora lutea                     |      |                              | d      | d    |    |
| Implantation sites                |      |                              |        | d    |    |
| Pre-implantation loss             |      | ic                           |        |      |    |
| Post-implantation loss            |      | ic                           | ic     |      |    |
| Resorptions                       |      | No treatment related effects |        |      |    |
| <b>Foetal evaluation (F2)</b>     |      |                              |        |      |    |
| Number of litters evaluated       | 20   | 20                           | 19     | 22   |    |
| Number of live foetuses           |      | No treatment related effects |        |      |    |
| Weight/sex/external abnormalities |      | No treatment related effects |        |      |    |

(A) Erythema was seen during the treatment period, but turned out to be completely reversible.

(B) Incidental significant increases of water consumption were seen at the highest dose groups.

(C) Slight keratinisation of the skin in females treated with 3.5 and 7.0%.

(D) An increased incidence of hydroureter and hydronephrosis in the 3.5% group was considered to be unrelated to treatment.

(E) The decrease in mean foetal weight was caused by very low weights of the pups in one litter only.

**Conclusions** NOAEL for maternal toxicity and reproductive effects = 7%.

- Rev. note**
1. The slightly decreased number of corpora lutea and/or implantation sites in the F1 of females treated at 3.5 and/or 7% remained within historical control values.
  2. The significant post-implantation loss in the F1 of the lower dosed females was not considered to be related to treatment, but due to total litter loss from one female at 1.75% and 3 females at 3.5%.
  3. No information on the use of a (semi)occlusive dressing was available. If no dressing is used, some oral intake of the test substance can not be fully excluded.
  4. The purity of the test substance is not indicated. Therefore, the actual amount (a.i.) applied can not be calculated.

**Klimisch criterium**

- 2 Non-GLP study; also Notes 3 and 4.